Document and Entity Information (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	May 01, 2015	Sep. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,296,021
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,684.6

Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Revenues
Net sales	$ 710,070	$ 592,454	$ 616,915
Other revenues	4,553	4,927	3,203
Total revenues	714,623	597,381	620,118
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	308,400	261,830	276,381
Gross profit	406,223	335,551	343,737
Operating Expenses
Advertising and promotion	99,651	84,968	87,151
General and administrative	81,273	48,481	51,467
Depreciation and amortization	17,740	13,486	13,235
Total operating expenses	198,664	146,935	151,853
Operating income	207,559	188,616	191,884
Other (income) expense
Interest income	(92)	(60)	(13)
Interest expense	81,326	68,642	84,420
Gain on sale of asset	1,133	0	0
Loss on extinguishment of debt	0	18,286	1,443
Total other expense	80,101	86,868	85,850
Income before income taxes	127,458	101,748	106,034
Provision for income taxes	49,198	29,133	40,529
Net income	78,260	72,615	65,505
Earnings per share:
Basic (in USD per share)	$ 1.50	$ 1.41	$ 1.29
Diluted (in USD per share)	$ 1.49	$ 1.39	$ 1.27
Weighted average shares outstanding:
Basic (in shares)	52,170	51,641	50,633
Diluted (in shares)	52,670	52,349	51,440
Comprehensive income, net of tax:
Currency translation adjustments	(24,151)	843	(91)
Total other comprehensive income (loss)	(24,151)	843	(91)
Comprehensive income	$ 54,109	$ 73,458	$ 65,414

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Current assets
Cash and cash equivalents	$ 21,318	$ 28,331
Accounts receivable, net	87,858	65,050
Inventories	74,000	65,586
Deferred income tax assets	8,097	6,544
Prepaid expenses and other current assets	10,434	11,674
Total current assets	201,707	177,185
Property and equipment, net	13,744	9,597
Goodwill	290,651	190,911
Intangible assets, net	2,134,700	1,394,817
Other long-term assets	28,603	23,153
Total Assets	2,669,405	1,795,663
Liabilities and Stockholders’ Equity
Accounts payable	46,115	48,286
Accrued interest payable	11,974	9,626
Other accrued liabilities	40,948	26,446
Total current liabilities	99,037	84,358
Long-term debt
Principal amount	1,593,600	937,500
Less unamortized discount	(4,889)	(3,086)
Long-term debt, net of unamortized discount	1,588,711	934,414
Deferred income tax liabilities	351,569	213,204
Other long-term liabilities	2,464	327
Total Liabilities	2,041,781	1,232,303
Commitments and Contingencies
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	0	0
Common stock-$0.01 par value; Authorized – 250,000 shares; Issued – 52,562 shares and 52,021 shares at March 31, 2015 and 2014, respectively	525	520
Additional paid-in capital	426,584	414,387
Treasury stock, at cost – 266 shares at March 31, 2015 and 206 shares at March 31, 2014	(3,478)	(1,431)
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings	227,405	149,145
Total Stockholders’ Equity	627,624	563,360
Total Liabilities and Stockholders’ Equity	$ 2,669,405	$ 1,795,663

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	52,562,000	52,021,000
Treasury stock, shares	266,000	206,000

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Preferred Share Rights	Retained Earnings (Accumulated Deficit)
Balances at Mar. 31, 2012	$ 402,728	$ 505	$ 391,898	$ (687)	$ (13)	$ 283	$ 10,742
Treasury stock, shares at Mar. 31, 2012				181,000
Common stock, shares at Mar. 31, 2012		50,466,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,772		3,772
Exercise of stock options	6,029	7	6,022
Exercise of stock options, shares	786,500	786,000
Issuance of shares related to restricted stock		1	(1)
Issuance of shares related to restricted stock, shares		59,000
Components of comprehensive income:
Net income	65,505						65,505
Translation adjustments	(91)				(91)
Comprehensive income	65,414
Balances at Mar. 31, 2013	477,943	513	401,691	(687)	(104)	283	76,247
Common stock, shares at Mar. 31, 2013		51,311,000
Treasury stock, shares at Mar. 31, 2013				181,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	5,146		5,146
Exercise of stock options	5,907	6	5,901
Exercise of stock options, shares	605,000	605,000
Preferred share rights	0	0				(283)	283
Issuance of shares related to restricted stock		1	(1)
Issuance of shares related to restricted stock, shares	0	105,000
Treasury share repurchases, shares				25,000
Treasury share repurchases	(744)			(744)
Excess tax benefits from share-based awards	1,650		1,650
Components of comprehensive income:
Net income	72,615						72,615
Translation adjustments	843				843
Comprehensive income	73,458
Balances at Mar. 31, 2014	563,360	520	414,387	(1,431)	739	0	149,145
Treasury stock, shares at Mar. 31, 2014	206,000			206,000
Common stock, shares at Mar. 31, 2014		52,021,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	6,918		6,918
Exercise of stock options	3,954	4	3,950
Exercise of stock options, shares	386,300	387,000
Issuance of shares related to restricted stock	0	1	(1)
Issuance of shares related to restricted stock, shares		154,000
Treasury share repurchases, shares				60,000
Treasury share repurchases	(2,047)			(2,047)
Excess tax benefits from share-based awards	1,330		1,330
Components of comprehensive income:
Net income	78,260						78,260
Translation adjustments	(24,151)				(24,151)
Comprehensive income	54,109
Balances at Mar. 31, 2015	$ 627,624	$ 525	$ 426,584	$ (3,478)	$ (23,412)	$ 0	$ 227,405
Treasury stock, shares at Mar. 31, 2015	266,000			266,000
Common stock, shares at Mar. 31, 2015		52,562,000

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Operating Activities
Net income	$ 78,260	$ 72,615	$ 65,505
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,740	13,486	13,235
Gain on sale of asset	(1,133)	0	0
Deferred income taxes	28,922	19,012	25,505
Long term income taxes payable	2,294	0	0
Amortization of deferred financing costs	6,735	7,102	9,832
Stock-based compensation costs	6,918	5,146	3,772
Loss on extinguishment of debt	0	18,286	1,443
Premium payment on 2010 Senior Notes	0	(15,527)	0
Amortization of debt discount	2,086	3,410	4,632
Lease termination costs	785	0	975
Loss (gain) on sale or disposal of property and equipment	321	(3)	103
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	1,608	9,735	(12,882)
Inventories	15,360	(2,850)	(9,342)
Prepaid expenses and other current assets	4,664	(2,130)	3,096
Accounts payable	(17,637)	(4,641)	24,677
Accrued liabilities	9,332	(12,059)	7,054
Net cash provided by operating activities	156,255	111,582	137,605
Investing Activities
Purchases of property and equipment	(6,101)	(2,764)	(10,268)
Proceeds from sale of property and equipment	0	3	15
Proceeds from the sale of business	0	0	21,700
Proceeds from sale of asset	10,000	0	0
Acquisition, less cash acquired	(749,666)	0	0
Acquisition of the Hydralyte brand	(77,991)	0	0
Acquisition of brands from GSK purchase price adjustments	0	0	226
Net cash (used in) provided by investing activities	(805,258)	(57,976)	11,221
Financing Activities
Proceeds from issuance of 2013 Senior Notes	0	400,000	0
Repayment of 2010 Senior Notes	0	(250,000)	0
Term loan borrowings	720,000	0	0
Term loan repayments	(130,000)	(157,500)	(190,000)
Borrowings under revolving credit agreement	124,600	50,000	48,000
Repayments under revolving credit agreement	(58,500)	(83,000)	(15,000)
Payment of deferred financing costs	(16,072)	(7,466)	(1,146)
Proceeds from exercise of stock options	3,954	5,907	6,029
Proceeds from restricted stock exercises	57	0	0
Excess tax benefits from share-based awards	1,330	1,650	0
Fair value of shares surrendered as payment of tax withholding	(2,104)	(744)	0
Net cash provided by (used in) financing activities	643,265	(41,153)	(152,117)
Effects of exchange rate changes on cash and cash equivalents	(1,275)	208	(54)
Increase (decrease) in cash and cash equivalents	(7,013)	12,661	(3,345)
Cash and cash equivalents - beginning of year	28,331	15,670	19,015
Cash and cash equivalents - end of year	21,318	28,331	15,670
Interest paid	70,155	62,357	69,641
Income taxes paid	11,939	11,020	10,624
Care Pharma
Investing Activities
Acquisition, less cash acquired	0	(55,215)	0
Disposal Group, Cutex
Investing Activities
Proceeds from the sale of business	$ 18,500	$ 0	$ 0

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2015”) mean our fiscal year ended on March 31st of that year.

Reclassification

We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2015 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized over the term of the related debt using the effective interest method.

Revenue Recognition

We recognize revenue when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss; and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $37.7 million for 2015, $32.0 million for 2014 and $30.6 million for 2013.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores’ shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The adoption of ASU 2015-03 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements.

In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items. The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements.

In November 2014, the FASB issued ASU 2014-17, Pushdown Accounting, which clarifies whether and at what threshold an acquired entity that is a business or nonprofit activity can apply pushdown accounting in its separate financial statements. This ASU provides companies with the option to apply pushdown accounting in its separate financial statements upon the occurrence of an event in which an acquirer obtains control of the acquired entity. The election to apply pushdown accounting can be made either in the period in which the change of control occurred, or in a subsequent period. The amendments in this update were effective November 18, 2014. The adoption of ASU 2014-17 did not have a material impact on our Consolidated Financial Statements.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our Consolidated Financial Statements.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

12 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Acquisitions

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading North American brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing. Insight is primarily included in our North American OTC Healthcare segment.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible assets	724,374
Total assets acquired	885,054

Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Based on this analysis, we allocated $599.6 million to indefinite-lived intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at March 31, 2015 was 15.6 years.

We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the year ended March 31, 2015 were $97.1 million. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
(In thousands, except per share data)	2015		2014
	(Unaudited)
Revenues	$	783,217	$	767,897
Net income	$	86,844	$	82,762

Earnings per share:
Basic	$	1.66	$	1.60

Diluted	$	1.65	$	1.58

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared a analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at March 31, 2015 was 11.8 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Goodwill

12 Months Ended

Mar. 31, 2015

Goodwill [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2013, 2014, and 2015:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2012
Goodwill	$	296,483		$	—		$	72,549		$	369,032
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2012	166,313			—			7,389			173,702

2013 additions	226			—			—			226
2013 reductions	(6,382		)	—			—			(6,382		)

Balance – March 31, 2013
Goodwill	290,327			—			72,549			362,876
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2013	160,157			—			7,389			167,546

2014 additions	—			23,122			—			23,122
Effects of foreign currency exchange rates	—			243			—			243

Balance – March 31, 2014
Goodwill	290,327			23,365			72,549			386,241
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015
Goodwill	393,581			20,440			71,960			485,981
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2015	$	263,411		$	20,440		$	6,800		$	290,651

During the three months ended June 30, 2012, we received a revised post-closing inventory and apportionment adjustment from GSK requiring an additional payment of $0.2 million, which resulted in an increase to our recorded goodwill balance.

As more fully disclosed in Note 3, on October 31, 2012, we sold the Phazyme brand for $22.3 million. As a result of the divestiture of Phazyme, we reduced goodwill by $6.4 million.

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired.

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.3 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

As further discussed in Note 8, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on the sale of such rights in the amount of $1.1 million and reduced the carrying value of our intangible assets and goodwill.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. During the fourth quarter of each fiscal year, we perform our annual impairment analysis. In prior years, we performed the analysis as of March 31. However, beginning with fiscal year 2015, we changed the date of our analysis to February 28 to better align with our annual operating plan preparation and to help facilitate our financial reporting process. We do not believe that a one-month change in the date of our analysis will significantly impact the results of our analysis or our financial statements.

At February 28, 2015 and March 31, 2014, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2015 or 2014.

We identify our reporting units in accordance with the FASB ASC Subtopic 280. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on key assumptions and valuation methodologies previously discussed. The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at February 28, 2015 and March 31, 2014 and 2013, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. Although the impairment charges recorded in the prior years were a result of utilizing management’s best estimate of fair value, the estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require additional impairments in the future. We have experienced significant declines in revenues and profitability of certain brands in the North American OTC Healthcare segment during 2015. In the past, we have experienced declines in revenues and profitability of certain brands in the North American OTC Healthcare and Household Cleaning segments. Sustained or significant future declines in revenue, profitability, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair value of certain brands could indicate that fair value no longer exceeds carrying value, in which case a non-cash impairment charge may be recorded in future periods.

The aggregate fair value of our reporting units exceeded the carrying value by 45.2% with no reporting unit's fair value exceeding the carrying value by less than 10%.

Intangible Assets

12 Months Ended

Mar. 31, 2015

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2013, 2014, and 2015 is as follows:



(In thousands)	Year Ended March 31, 2013
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2012	$	1,245,414		$	217,512		$	158	$	1,463,084
Reclassifications	(1,696		)	1,696			—		—
Reductions	—			(16,142		)	—		(16,142		)
Balance – March 31, 2013	$	1,243,718		$	203,066		$	158	$	1,446,942

Accumulated Amortization
Balance – March 31, 2012	$	—		$	62,404		$	158	$	62,562
Additions	—			11,678			—		11,678
Reductions	—			(538		)	—		(538		)
Balance – March 31, 2013	$	—		$	73,544		$	158	$	73,702

Intangibles, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,898		$	101,611		$	—	$	1,225,509
International OTC Healthcare	—			—			—		—
Household Cleaning	119,820			27,911			—		147,731
Intangible assets, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240



(In thousands)	Year Ended March 31, 2014
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	$	—	$	83,801	$	—		$	83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,897	$	93,242	$	—		$	1,217,139
International OTC Healthcare	30,161		1,530		—			31,691
Household Cleaning	119,820		26,167		—			145,987
Intangible assets, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817



(In thousands)	Year Ended March 31, 2015
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	—	$	1,478,618
Additions	673,180			124,774			—		797,954
Reclassifications	(46,506		)	46,506			—		—
Reductions	(9,548		)	(17,674		)	—		(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	—		(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	—	$	83,801
Additions	—			12,995			—		12,995
Effects of foreign currency exchange rates	—			(26		)	—		(26		)
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	—	$	1,912,633
International OTC Healthcare	86,141			1,231			—		87,372
Household Cleaning	110,272			24,423			—		134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

In conjunction with our annual impairment analysis, we reassessed the useful lives of our intangible assets and determined that our Pediacare trade name should be reclassified to a finite-lived intangible asset with an estimated 20 year useful life. We made this determination based on the recent declines in the business and a strategic change in the focus of certain brands as we continue to prioritize our support on other significant and more recently acquired brands.

As discussed in Note 3, on October 31, 2012, we sold the Phazyme brand for $22.3 million. As a result of this divestiture, we reduced the net book value of our intangible assets by $15.6 million.

During the year ended March 31, 2013, we reclassified a portion of trademarks related to the acquired GSK brands from indefinite-lived to finite-lived intangible assets in the amount of $1.7 million.

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our analysis.

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to intangible assets.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

During the fourth quarter of each fiscal year, we perform our annual impairment analysis. In prior years, we performed the analysis as of March 31. However, beginning with fiscal year 2015, we changed the date of our analysis to February 28 to better align with our annual operating plan preparation and to help facilitate our financial reporting process. We do not believe that a one-month change in the date of our analysis will significantly impact the results of our analysis or our financial statements.

We utilized the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future. In addition, we considered our market capitalization at February 28, 2015, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we determined that the fair values exceeded the carrying values and as such, no impairment charge was recorded in 2015.

Based on our analysis, the aggregate fair value of our reporting units exceeded the carrying value by 45.2%, with no reporting unit's fair value exceeding the carrying value by less than 10%. The aggregate fair value of the indefinite-lived intangible assets exceeded the carrying value by 42.4%. Three of the individual indefinite-lived trade names exceeded their carrying values by less than 10%. The fair value of Debrox, New Skin and Ecotrin, exceed their carrying values of $76.3 million, $37.2 million and $32.9 million, by 8.3%, 9.2% and 7.9%, respectively.

The significant assumptions underpinning the fair value of Debrox include a discount rate of 10%, coupled with modest revenue growth, and advertising and promotion investments that are in line with historical performance. A decrease in the annual cash flow of approximately 7.7% compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 62 basis points could result in the carrying value of our trade name exceeding its fair value, resulting in an impairment charge.

The significant assumptions supporting the fair value of New Skin and Ecotrin, include a discount rate of 10% and cash flow projections that assume stabilizing revenue declines followed by modest revenue growth. Gross margin and advertising and promotion investments behind the brands are expected to be consistent with historic trends. Continued revenue declines in each of the brands, or changes in assumptions utilized in our quantitative indefinite lived asset impairment analysis may result in the fair value no longer exceed their carrying values. For example, a decrease in the annual cash flow of approximately 8.4% and 7.3%, for New Skin and Ecotrin, respectively, compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 77 and 72 basis points, respectively, could result in the carrying value of our trade name exceeding its fair value, resulting in an impairment charge. We will continue to review our results against forecasts and assess our assumptions to ensure they continue to be appropriate.

Additionally, certain of our North American OTC Healthcare and Household Cleaning brands, have experienced recent declines in revenues and profitability. While the fair value of these reporting units exceeds the carrying value by more than 10%, should such revenue declines continue, the fair value of the corresponding reporting units may no longer exceed their carrying value and we would be required to record an impairment charge.

Revenues from our Pediacare brand have declined significantly as compared to the corresponding periods in the prior year, due primarily to competition in the category, including new product introductions and lost distribution. Although we had expected revenues to decline with the return to the market of competing products, such declines have been steeper than expected. As a result, we performed an interim impairment analysis during our third quarter ended December 31, 2014 and concluded that no impairment existed. Additionally, in conjunction with a strategic review of our brands during the fourth quarter ended March 31, 2015 and our annual impairment review, we have reassessed the useful life of the Pediacare brand as of February 28, 2015 and determined it to be 20 years.

See Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under the heading "Critical Accounting Policies" for a further discussion on the assumptions used in our impairment analysis. Furthermore, we completed our annual test for impairment of intangible assets during the fourth quarter of each of the years presented and did not record an impairment charge, as facts and circumstances indicated that the fair values of each intangible asset exceeded its carrying value. Adverse changes in the expected operating results and/or unfavorable changes in other economic factors used to estimate fair values of these specific brands could result in a non-cash impairment charge in the future.

The weighted average remaining life for finite-lived intangible assets at March 31, 2015 was approximately 14.6 years and the amortization expense for the year ended March 31, 2015 was $13.0 million. At March 31, 2015, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2016	17,868
2017	17,868
2018	17,868
2019	17,868
2020	17,868
Thereafter	171,956
	$	261,296

Sale of asset

Historically, we received royalty income from the licensing of the name of certain of our brands in geographic areas or markets in which we do not directly compete. We have had a royalty agreement for our Comet brand for several years, which included an option on behalf of the licensee to purchase the rights in certain geographic areas and markets in perpetuity. In December 2014, we amended the agreement to allow the licensee to buy out a portion of the agreement early, but retaining the remaining stream of royalty payments. In December, in connection with this amendment, we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee and received $10.0 million as a partial early buyout. As a result, we recorded a gain on sale of $1.1 million, and reduced the carrying value of our intangible assets and goodwill. The licensee will continue to make quarterly payments at least through June 30, 2016 of approximately $1.0 million. The licensee has the option to purchase the remaining territories and markets, as defined in the agreement, at any time after July 1, 2016.

Long-Term Debt

12 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the year ended March 31, 2015, the average interest rate on the 2012 Term Loan was 5.3%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make another payment until the maturity date of January 31, 2019.

On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the year ended March 31, 2015, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.8%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Redemptions and Restrictions:

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we could redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At March 31, 2015, we were in compliance with the covenants under our long-term indebtedness.

At March 31, 2015, we had an aggregate of $28.6 million of unamortized debt issuance costs and $4.9 million of unamortized debt discount, the total of which is comprised of $8.7 million related to the 2012 Senior Notes, $6.2 million related to the 2013 Senior Notes, $17.4 million related to the 2012 Term Loan, and $1.2 million related to the 2012 ABL Revolver.

At March 31, 2015, we had $66.1 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $44.9 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2015			March 31, 2014
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	217,500			287,500
2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	660,000			—
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
	1,593,600			937,500
Current portion of long-term debt	—			—
	1,593,600			937,500
Less: unamortized discount	(4,889		)	(3,086		)
Long-term debt, net of unamortized discount	$	1,588,711		$	934,414

As of March 31, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2016	$	—
2017	66,100
2018	—
2019	217,500
2020	250,000
Thereafter	1,060,000
	$	1,593,600

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements As we deem appropriate, we may from time to time utilize derivative financial instruments to mitigate the impact of changing interest rates associated with our long-term debt obligations or other derivative financial instruments. While we have utilized derivative financial instruments in the past, we did not have any significant derivative financial instruments outstanding at March 31, 2015, 2014 or 2013. We have not entered into derivative financial instruments for trading purposes; all of our derivatives were over-the-counter instruments with liquid markets. For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-1 Loans, Term B-2 Loans, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At March 31, 2015 and 2014, we did not have any assets or liabilities measured in Level 1 or 3. During 2015, 2014 and 2013, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At March 31, 2015 and 2014, the carrying value of our 2013 Senior Notes was $400.0 million and $400.0 million, respectively. At March 31, 2015 and 2014, the fair value of our 2013 Senior Notes was $405.0 million and $408.5 million, respectively. At March 31, 2015 and 2014, the carrying value of our 2012 Senior Notes was $250.0 million and $250.0 million, respectively. The fair value of our 2012 Senior Notes was $268.1 million and $280.6 million at March 31, 2015 and 2014, respectively. At March 31, 2015 and 2014, the carrying value of the Term B-1 Loans was $217.5 million and $287.5 million, respectively. The fair value of the Term B-1 Loans was $218.0 million and $288.9 million at March 31, 2015 and 2014, respectively. At March 31, 2015, the carrying value of the Term B-2 Loans was $660.0 million. The fair value of the Term B-2 Loan was $662.5 million at March 31, 2015. Because the Term B-2 Loans were entered into on September 3, 2014, there were no outstanding loan balances as of March 31, 2014. At March 31, 2015, the carrying value and fair value of the 2012 ABL Revolver was $66.1 million and $65.7 million, respectively. There were no outstanding borrowings under the 2012 ABL Revolver at March 31, 2014.

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2015. Pursuant to the provisions of various employee restricted stock awards, we repurchased 59,933 shares and 25,464 shares of restricted common stock from our employees during the years ended March 31, 2015 and 2014, respectively. The repurchases during the years ended March 31, 2015 and 2014 were at an average price of $34.16 and $29.23, respectively. All of the repurchased shares have been recorded as treasury stock.

Earnings Per Share

12 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



(In thousands, except per share data)	Year Ended March 31,
	2015		2014		2013
Numerator
Net income	$	78,260	$	72,615	$	65,505

Denominator
Denominator for basic earnings per share- weighted average shares outstanding	52,170		51,641		50,633
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	500		708		807
Denominator for diluted earnings per share	52,670		52,349		51,440

Earnings per Common Share:
Basic net earnings per share	$	1.50	$	1.41	$	1.29

Diluted net earnings per share	$	1.49	$	1.39	$	1.27

Additionally, for 2015, 2014, and 2013 there were 0.3 million, 0.2 million, and zero shares attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

12 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants, up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance thereunder and increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1 million to 2.5 million shares and extended the term of the Plan by 10 years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2015, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $6.9 million and $1.9 million, respectively.

During 2014, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $5.1 million and $1.5 million, respectively.

During 2013, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $3.8 million and $1.2 million, respectively.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

On May 9, 2012, the Compensation Committee of our Board of Directors granted 111,152 restricted stock units to certain executive officers and employees under the Plan, which will vest 33.3% per year over three years. On June 29, 2012, the Compensation Committee of our Board of Directors granted 12,652 restricted stock units to the independent members of the Board of Directors under the Plan. On August 6, 2012, the Compensation Committee of the Board of Directors granted 5,109 restricted stock units to Matthew M. Mannelly, our President and CEO, under the Plan. On May 14, 2013, the Compensation Committee of our Board of Directors granted 113,637 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 55,637 restricted stock units vest in their entirety on the three-year anniversary of the date of grant, and 58,000 restricted stock units vest 33.3% per year over three years. On July 29, 2013, the Compensation Committee of the Board of Directors granted 7,004 restricted stock units to the independent members of the Board of Directors under the Plan. On November 5, 2013, the Compensation Committee of our Board of Directors granted 6,000 restricted stock units to certain employees under the Plan, which will vest 33.3% per year over three years. On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 75,638 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 restricted stock units vest 33.3% per year over three years. On August 5, 2014, the Compensation Committee of our Board of Directors granted 7,796 restricted stock units to the independent members of the Board of Directors under the Plan. On August 14, 2014, pursuant to his employment agreement, the Compensation Committee of the Board of Directors granted 2,489 restricted stock units to Thomas Hochuli, our Vice-President of Operations, under the Plan.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of the grant. The weighted-average grant-date fair value during 2015, 2014, and 2013 was $33.33, $30.19 and $13.59, respectively.

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value

Vested and Nonvested at March 31, 2012	363.4		$	9.92

Granted	128.9		13.59
Vested and issued	(58.7	)	9.99
Forfeited	(12.3	)	10.69
Vested and nonvested at March 31, 2013	421.3		11.01
Vested at March 31, 2013	70.4		8.52

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

On May 9, 2012, the Compensation Committee of our Board of Directors granted stock options to acquire 422,962 shares of our common stock to certain executive officers and employees under the Plan. These stock options were granted at an exercise price of $13.24 per share, which is equal to the closing price for our common stock on the date of the grant. On August 6, 2012, the Compensation Committee of the Board of Directors granted stock options to acquire 21,978 shares of our common stock to Matthew M. Mannelly. These stock options were granted at an exercise price of $15.66 per share, which is equal to the closing price for our common stock on the date of grant. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. On May 14, 2013, the Compensation Committee of our Board of Directors granted stock options to acquire 227,672 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.94 per share, which is equal to the closing price for our common stock on the date of grant. On May 12, 2014, the Compensation Committee of our Board of Directors granted stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the date of grant. On August 14, 2014, pursuant to his employment agreement, the Compensation Committee of our Board of Directors granted stock options to acquire 10,485 shares of our common stock to Thomas Hochuli, our Vice-President of Operations, under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $34.79 per share, which is equal to the closing price for our common stock on the date of grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options.

The weighted-average grant-date fair values of the options granted during 2015, 2014, and 2013 were $15.95, $13.94, and $6.03, respectively.



	Year Ended March 31,
	2015		2014
Expected volatility	47.3	%	48.0	%
Expected dividends	—		—
Expected term in years	6.0		6.0
Risk-free rate	2.2	%	1.3	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2012	1,745.4		$	8.44

Granted	444.9		13.36
Exercised	(786.5	)	7.67
Forfeited or expired	(17.4	)	11.21
Outstanding at March 31, 2013	1,386.4		10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40		7.7	$	16,978
Exercisable at March 31, 2015	312.3		15.15		6.4	8,664

The aggregate intrinsic value of options exercised during 2015 was $9.3 million.

At March 31, 2015, there were $4.9 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 years. The total fair value of options and restricted stock units vested during 2015, 2014, and 2013 was $4.7 million, $3.4 million and $2.5 million, respectively. Cash received from the exercise of stock options was $4.0 million during 2015, and we realized $2.2 million in tax benefits for the tax deductions resulting from option exercises in 2015. Cash received from the exercise of stock options was $5.9 million during 2014, and we realized $1.7 million in tax benefits for the tax deductions resulting from option exercises in 2014. Cash received from the exercise of stock options was $6.0 million during 2013, and we realized $11.3 million in tax benefits for the tax deductions from option exercises in 2013. On August 5, 2014 at the Annual Meeting of Stockholders, the stockholders approved the proposal to amend the Plan. The amendment authorized an additional 1.8 million shares of our common stock for issuance thereunder, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares and extended the term of the Plan by 10 years, until February 2025. At March 31, 2015, there were 3.0 million shares available for issuance under the Plan.

Income Taxes

12 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

Income from continuing operations before income taxes consists of the following:



	Year Ended March 31,
	2015		2014		2013
(In thousands)
United States	$	122,588	$	98,786	$	105,727
Foreign	4,870		2,962		307
	$	127,458	$	101,748	$	106,034

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2015			2014			2013
Current
Federal	$	13,066		$	7,801		$	12,520
State	760			625			1,972
Foreign	3,228			1,675			532
Deferred
Federal	31,012			27,045			23,845
State	1,162			(7,879		)	1,660
Foreign	(30		)	(134		)	—
Total provision for income taxes	$	49,198		$	29,133		$	40,529

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2015			2014
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	4,106		$	4,082
Inventory capitalization	1,550			1,301
Inventory reserves	1,495			362
Net operating loss carryforwards	23,800			327
State income taxes	7,557			3,728
Accrued liabilities	619			642
Stock compensation	3,517			2,358
Other	834			702
Total deferred tax assets	43,478			13,502

Deferred Tax Liabilities
Property and equipment	(1,143		)	(1,467		)
Intangible assets	(385,807		)	(218,696		)
Total deferred tax liabilities	(386,950		)	(220,163		)

Net deferred tax liability	$	(343,472	)	$	(206,661	)

At March 31, 2015, a 100% owned subsidiary of the Company had a net operating loss carryforward of approximately $65.0 million ($23.8 million, tax effected), which may be used to offset future taxable income of the consolidated group and begins to expire in 2025. The Company expects to fully utilize the loss carryover before it expires. The net operating loss carryforward is subject to an annual limitation as to usage under Internal Revenue Code Section 382 of approximately $33.0 million.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
(In thousands)	2015					2014					2013
				%					%					%
Income tax provision at statutory rate	$	44,610		35.0		$	35,612		35.0		$	37,112		35.0
Foreign tax (benefit) provision	(2,019		)	(1.6	)	(918		)	(0.9	)	—			—
State income taxes, net of federal income tax benefit	2,865			2.3		2,004			2.0		3,413			3.2
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	—			—		(8,892		)	(8.7	)	(1,741		)	(1.6	)
Goodwill impairment	206			0.2		—			—		—			—
Transaction costs	2,936			2.3		—			—		—			—
Nondeductible compensation	566			0.4		1,011			1.0		1,684			1.6
Other	34			—		316			0.3		61			—
Total provision for income taxes	$	49,198		38.6		$	29,133		28.7		$	40,529		38.2

Uncertain tax liability activity is as follows:



	2015			2014			2013
(In thousands)
Balance – beginning of year	$	1,236		1,016			292
Additions based on tax positions related to the current year	2,229			360			831
Reductions based on lapse of statute of limitations	(45		)	(140		)	(107		)
Balance – end of year	$	3,420		$	1,236		$	1,016

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in 2013, 2014 or 2015. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during 2016. We are subject to taxation in the United States and various state and foreign jurisdictions and we are generally open to examination from the year ended March 31, 2012 forward.

The Company does not provide for United States income taxes on the undistributed earnings of foreign subsidiaries, which are intended to be indefinitely reinvested in operations outside of the United States. As of March 31, 2015, the cumulative amount of earnings upon which United States income taxes have not been provided is approximately $14.2 million. As of March 31, 2015, the amount of unrecognized deferred tax liability related to these earnings is estimated to be $1.3 million.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. We required additional office space as a result of the closing of the acquisition of Insight. Therefore, in the first quarter of fiscal 2015, we amended our existing New York office lease to include an additional 15,470 square feet beginning October 2014 and extended the expiration of the combined lease through September 2020. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2016	$	1,612	$	311	$	1,923
2017	1,772		77		1,849
2018	1,856		—		1,856
2019	1,864		—		1,864
2020	2,465		—		2,465
	$	9,569	$	388	$	9,957

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.4 million due in the future under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2015			2014
Minimum lease payments	$	9,957		$	4,621
Less: Sublease rentals	(1,401		)	—
	$	8,556		$	4,621

Rent expense was $1.6 million, $1.5 million, and $1.2 million for 2015, 2014, and 2013, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,
2016	1,074
2017	1,044
2018	1,013
2019	982
2020	560
Thereafter	—
	$	4,673

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During 2015, 2014, and 2013, approximately 38.2%, 38.3%, and 40.5%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2015, 2014, and 2013, Walmart accounted for approximately 18.1%, 19.5%, and 15.9%, respectively, of our gross revenues. At March 31, 2015, approximately 23.0% and 10.5% of accounts receivable were owed by Walmart and Walgreens, respectively. Our next largest customer accounted for approximately 8.4% of our gross revenues during 2015. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At March 31, 2015, we had relationships with 95 third-party manufacturers. Of those, we had long-term contracts with 44 manufacturers that produced items that accounted for approximately 82.9% of our gross sales for 2015, compared to 24 manufacturers with long-term contracts that accounted for approximately 82.4% of gross sales in 2014. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach agreement which could have a material adverse effect on our business.

Business Segments

12 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Business Segments

Beginning April 1, 2014, we began managing and reporting certain of our businesses separately and have therefore realigned our reportable segments to align with how we manage and evaluate the results of our business. These reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. The results of our previously reported OTC Healthcare segment is now separated into two reporting segments, the North American OTC Healthcare segment and the International OTC Healthcare segment, largely to reflect our international expansion due to recent acquisitions. Prior year amounts were reclassified to conform to the current reportable segments discussed above. Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The table below summarizes information about our operating and reportable segments.



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	566,256		$	61,116	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	562,869			61,116		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	563,506			61,180		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	346,725			38,360		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	259,828		$	27,438	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	482,138		$	29,872	$	83,629	$	595,639
Elimination of intersegment revenues	(3,185		)	—		—		(3,185		)
Third-party segment revenues	478,953			29,872		83,629		592,454
Other revenues	749			42		4,136		4,927
Total segment revenues	479,702			29,914		87,765		597,381
Cost of sales	184,796			12,646		64,388		261,830
Gross profit	294,906			17,268		23,377		335,551
Advertising and promotion	77,083			5,264		2,621		84,968
Contribution margin	$	217,823		$	12,004	$	20,756	250,583
Other operating expenses								61,967
Operating income								188,616
Other expense								86,868
Income before income taxes								101,748
Provision for income taxes								29,133
Net income								$	72,615



	Year Ended March 31, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	519,046	$	14,493	$	83,376	$	616,915
Elimination of intersegment revenues	—		—		—		—
Third-party segment revenues	519,046		14,493		83,376		616,915
Other revenues	639		45		2,519		3,203
Total segment revenues	519,685		14,538		85,895		620,118
Cost of sales	205,389		6,265		64,727		276,381
Gross profit	314,296		8,273		21,168		343,737
Advertising and promotion	80,051		1,643		5,457		87,151
Contribution margin	$	234,245	$	6,630	$	15,711	256,586
Other operating expenses							64,702
Operating income							191,884
Other expense							85,850
Income before income taxes							106,034
Provision for income taxes							40,529
Net income							$	65,505



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	81,849		16,076		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	563,506	$	61,180	$	89,937	$	714,623



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	108,101	$	1,883	$	—	$	109,984
Cough & Cold	100,060		13,365		—		113,425
Women's Health	1,960		1,835		—		3,795
Gastrointestinal	81,469		838		—		82,307
Eye & Ear Care	75,568		9,923		—		85,491
Dermatologicals	56,436		1,655		—		58,091
Oral Care	47,900		413		—		48,313
Other OTC	8,208		2		—		8,210
Household Cleaning	—		—		87,765		87,765
Total segment revenues	$	479,702	$	29,914	$	87,765	$	597,381



	Year Ended March 31, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	107,272	$	245	$	—	$	107,517
Cough & Cold	121,514		4,277		—		125,791
Women's Health	2,544		—		—		2,544
Gastrointestinal	97,536		82		—		97,618
Eye & Ear Care	76,960		9,116		—		86,076
Dermatologicals	56,114		399		—		56,513
Oral Care	49,002		419		—		49,421
Other OTC	8,743		—		—		8,743
Household Cleaning	—		—		85,895		85,895
Total segment revenues	$	519,685	$	14,538	$	85,895	$	620,118

During fiscal 2015, 2014, and 2013, approximately 85.2%, 86.9%, and 89.9%, respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of total segment revenues in any of the periods presented. During fiscal 2015, 2014, and 2013, our Canada sales accounted for approximately 5.9%, 7.7%, and 7.4%, respectively, of our total segment revenues, while during fiscal 2015, our Australia sales accounted for approximately 6.9% of our total segment revenues.

At March 31, 2015, approximately 95.6% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.4% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	20,440	$	6,800	$	290,651

Intangible assets
Indefinite-lived	1,676,991		86,141		110,272		1,873,404
Finite-lived	235,642		1,231		24,423		261,296
Intangible assets, net	1,912,633		87,372		134,695		2,134,700
Total	$	2,176,044	$	107,812	$	141,495	$	2,425,351

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2015 and 2014 is as follows:

Year Ended March 31, 2015



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2014		September 30, 2014			December 31, 2014			March 31, 2015
Total revenues	$	145,702	$	181,269		$	197,606		$	190,046
Cost of sales (exclusive of depreciation shown below)	63,836		78,727			85,861			79,976
Gross profit	81,866		102,542			111,745			110,070

Operating expenses
Advertising and promotion	19,096		25,044			30,144			25,367
General and administrative	17,006		27,128			19,454			17,685
Depreciation and amortization	2,961		3,852			5,154			5,773
	39,063		56,024			54,752			48,825
Operating income	42,803		46,518			56,993			61,245
Net interest expense	14,653		18,193			24,592			23,796
Gain on sale of asset	—		—			(1,133		)	—
Income before income taxes	28,150		28,325			33,534			37,449
Provision for income taxes	11,418		11,862			12,241			13,677
Net income	$	16,732	$	16,463		$	21,293		$	23,772


Earnings per share:
Basic	$	0.32	$	0.32		$	0.41		$	0.45
Diluted	$	0.32	$	0.31		$	0.40		$	0.45

Weighted average shares outstanding:
Basic	51,956		52,088			52,278			52,356
Diluted	52,533		52,594			52,730			52,821

Comprehensive income, net of tax:
Currency translation adjustments	2,726		(10,830		)	(8,779		)	(7,268		)
Total other comprehensive income (loss)	2,726		(10,830		)	(8,779		)	(7,268		)
Comprehensive income	$	19,458	$	5,633		$	12,514		$	16,504

Year Ended March 31, 2014



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2013		September 30, 2013		December 31, 2013			March 31, 2014
Total revenues	$	142,512	$	166,945	$	144,871		$	143,053
Cost of sales (exclusive of depreciation shown below)	59,488		73,723		64,403			64,216
Gross profit	83,024		93,222		80,468			78,837

Operating expenses
Advertising and promotion	18,681		24,547		24,229			17,511
General and administrative	11,634		11,619		12,137			13,091
Depreciation and amortization	3,268		3,294		3,644			3,280
	33,583		39,460		40,010			33,882
Operating income	49,441		53,762		40,458			44,955
Net interest expense	15,905		16,439		21,260			14,978
Loss on extinguishment of debt	—		—		15,012			3,274
Income before income taxes	33,536		37,323		4,186			26,703
Provision for income taxes	12,844		4,531		1,056			10,702
Net income (loss)	$	20,692	$	32,792	$	3,130		$	16,001

Earnings per share:
Basic	$	0.40	$	0.64	$	0.06		$	0.31
Diluted	$	0.40	$	0.63	$	0.06		$	0.30

Weighted average shares outstanding:
Basic	51,222		51,463		51,806			51,893
Diluted	52,040		52,219		52,445			52,513

Comprehensive income, net of tax:
Currency translation adjustments	1		1,122		(2,694		)	2,414
Total other comprehensive income (loss)	1		1,122		(2,694		)	2,414
Comprehensive income	$	20,693	$	33,914	$	436		$	18,415

Condensed Consolidating Financial Statements

12 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of March 31, 2015 and 2014 and Condensed Consolidating Income and Comprehensive Income Statements and Condensed Consolidating Statements of Cash Flows for each year in the three year period ended March 31, 2015. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the Issuer or the Borrower,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Annual Report on Form 10-K for the fiscal year ended March 31, 2015.

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	97,509		$	474,338		$	23,286		$	(2,679	)	$	592,454
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total revenues	—			97,804			479,224			24,925			(4,572		)	597,381

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			60,532			260,532			15,497			(1,010		)	335,551

Advertising and promotion	—			10,223			69,583			5,162			—			84,968
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			18,826			113,767			8,208			—			146,935
Operating income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868
Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748
Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	102,203		$	510,041		$	4,671		$	—		$	616,915
Other revenues	—			278			3,158			1,517			(1,750		)	3,203
Total revenues	—			102,481			513,199			6,188			(1,750		)	620,118

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,333			236,795			2,003			(1,750		)	276,381
Gross profit	—			63,148			276,404			4,185			—			343,737

Advertising and promotion	—			12,102			73,623			1,426			—			87,151
General and administrative	5,127			6,917			38,713			710			—			51,467
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Total operating expenses	6,473			19,588			123,597			2,195			—			151,853
Operating (loss) income	(6,473		)	43,560			152,807			1,990			—			191,884

Other (income) expense
Interest income	(30,561		)	(57,496		)	—			(1		)	88,045			(13		)
Interest expense	34,671			84,420			53,374			—			(88,045		)	84,420
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Total other expense (income)	(68,185		)	(37,417		)	51,892			(1		)	139,561			85,850
Income (loss) before income taxes	61,712			80,977			100,915			1,991			(139,561		)	106,034
Provision (benefit) for income taxes	(3,793		)	5,807			38,006			509			—			40,529
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505

Comprehensive income, net of tax:
Currency translation adjustments	(91		)	—			—			(91		)	91			(91		)
Total other comprehensive (loss) income	(91		)	—			—			(91		)	91			(91		)
Comprehensive income (loss)	$	65,414		$	75,170		$	62,909		$	1,391		$	(139,470	)	$	65,414

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			28,603			—			—			—			28,603
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,146,720		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,669,405

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized discount	—			(4,889		)	—			—			—			(4,889		)
Long-term debt, net of unamortized discount	—			1,588,711			—			—			—			1,588,711

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,668,924			1,633,323			77,274			(4,494,004		)	2,041,781

Stockholders' Equity
Common stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost - 266 shares	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders' Equity	$	2,783,888		$	4,146,720		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,669,405

Condensed Consolidating Balance Sheet

March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185

Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358

Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414

Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303

Stockholders' Equity
Common Stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders’ Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long term income taxes payable	—			—			2,294			—			—			2,294
Amortization of deferred financing costs	—			6,735			—			—			—			6,735
Stock-based compensation costs	6,918			—			—			—			—			6,918
Amortization of debt discount	—			2,086			—			—			—			2,086
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from sale of business	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effects of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of deferred financing costs	—			7,102			—			—			—			7,102
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment on 2010 Senior Notes	—			(15,527		)	—			—			—			(15,527		)
Amortization of debt discount	—			3,410			—			—			—			3,410
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash used in investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Term loan repayments	—			(157,500		)	—			—			—			(157,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayment under revolving credit agreement	—			(83,000		)	—			—			—			(83,000		)
Payment of deferred financing costs	—			(7,466		)	—			—			—			(7,466		)
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Deferred income taxes	138			4,341			21,036			(10		)	—			25,505
Amortization of deferred financing costs	—			9,832			—			—			—			9,832
Stock-based compensation costs	3,772			—			—			—			—			3,772
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Amortization of debt discount	—			4,632			—			—			—			4,632
Lease termination costs	975			—			—			—			—			975
Loss on disposal of equipment	82			—			21			—			—			103
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Changes in operating assets and liabilities
Accounts receivable	4			(373		)	(12,391		)	(122		)	—			(12,882		)
Inventories	—			(3,066		)	(6,360		)	84			—			(9,342		)
Prepaid expenses and other current assets	3,160			(37		)	(135		)	108			—			3,096
Accounts payable	(1,930		)	5,784			20,687			136			—			24,677
Accrued liabilities	(39		)	2			7,069			22			—			7,054
Net cash provided by operating activities	718			32,513			102,615			1,759			—			137,605

Investing Activities
Purchases of property and equipment	(10,268		)	—			—			—			—			(10,268		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of brands from GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(10,494		)	—			21,715			—			—			11,221

Financing Activities
Term loan repayments	—			(190,000		)	—			—			—			(190,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Repayments under revolving credit agreement	—			(15,000		)	—			—			—			(15,000		)
Payment of deferred financing costs	—			(1,146		)	—			—			—			(1,146		)
Proceeds from exercise of stock options	6,029			—			—			—			—			6,029
Intercompany activity, net	246			125,633			(124,330		)	(1,549		)	—			—
Net cash (used in) provided by financing activities	6,275			(32,513		)	(124,330		)	(1,549		)	—			(152,117		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(54		)	—			(54		)
(Decrease) increase in cash and cash equivalents	(3,501		)	—			—			156			—			(3,345		)
Cash and cash equivalents - beginning of year	18,221			—			—			794			—			19,015
Cash and cash equivalents - end of year	$	14,720		$	—		$	—		$	950		$	—		$	15,670

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Debt Refinancing: On May 8, 2015, the Borrower entered into Amendment No. 3 (the "Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provides for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the current outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loan of $645.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on the Term B-3 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75%, or an alternate base rate, with a floor of 1.75%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). The maturity date remains the same as the Term B-2 Loans original maturity date of September 3, 2021. In May 2015, the Borrower also entered into negotiations for Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extends the maturity date to 5 years from the closing date. We expect to close this transaction in the first quarter of fiscal 2016. Share based compensation: On May 11, 2015, the Compensation Committee of our Board of Directors granted 185,904 shares of restricted common stock units and stock options to acquire 186,302 shares of our common stock to certain executive officers and employees under the Plan. 163,404 shares of restricted common stock units vest in their entirety on the three-year anniversary of the date of grant and 22,500 shares of restricted common stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $41.44 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested restricted common stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan. Election of Director: On May 11, 2015, James M. Jenness, retired Chairman of the Board and CEO of the Kellogg Company, was elected to the Company's board of directors. Mr. Jenness, 68, served as Chairman of the Board of Kellogg Company, a producer of cereal and convenience foods, from February 2005 to June 2014, and as Chief Executive Officer from 2004-2006. He has served as a director of Kellogg since 2007 and as a director of Kimberly-Clark Corporation, a producer of personal care products, since 2007. His background also includes serving as Chief Executive Officer of Integrated Merchandising Systems, LLC, a retail promotion and merchandising company, and a 22 year career with Leo Burnett Company, Inc., the global advertising agency, where he last served as Vice Chairman and Chief Operating Officer. Chief Executive Officer Retirement: On April 22, 2015, we announced that Matthew M. Mannelly, our President and Chief Executive Officer and member of the Board of Directors, will retire effective June 1, 2015. In conjunction with his retirement, the Board of Directors has accelerated the vesting of his previously unvested restricted stock units and stock options and we expect to record additional stock based compensation of approximately $0.8 million associated with this acceleration. Following his retirement, and effective June 1, 2015, the Board of Directors has appointed Ron Lombardi, our current Chief Financial Officer, to succeed Mr. Mannelly as President and Chief Executive Officer and as a member of the Board of Directors. The company has commenced a search for a new Chief Financial Officer, and Mr. Lombardi will also remain as Chief Financial Officer until his successor is elected.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2015

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year		Amounts Charged to Expense		Deductions			Other		Balance at End of Year
Year Ended March 31, 2015
Reserves for sales returns and allowance	$	7,395	$	34,598	$	(35,277	)	$	—	$	6,716
Reserves for trade promotions	6,101		60,499		(56,668		)	—		9,932
Reserves for consumer coupon redemptions	1,742		5,089		(5,159		)	—		1,672
Allowance for doubtful accounts	1,035		340		(98		)	—		1,277

Year Ended March 31, 2014
Reserves for sales returns and allowance	6,446		38,314		(37,365		)	—		7,395
Reserves for trade promotions	8,523		39,967		(42,389		)	—		6,101
Reserves for consumer coupon redemptions	4,249		2,755		(5,262		)	—		1,742
Allowance for doubtful accounts	863		134		(6		)	44		1,035

Year Ended March 31, 2013
Reserves for sales returns and allowance	4,257		33,165		(30,976		)	—		6,446
Reserves for trade promotions	5,506		41,041		(38,024		)	—		8,523
Reserves for consumer coupon redemptions	3,509		8,282		(7,542		)	—		4,249
Allowance for doubtful accounts	604		265		(6		)	—		863

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Reclassification

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Financing Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Acquisitions (Tables)

12 Months Ended

Mar. 31, 2015

Insight Pharmaceuticals Corporation

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible assets	724,374
Total assets acquired	885,054

Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Pro Forma Information



	Year Ended March 31,
(In thousands, except per share data)	2015		2014
	(Unaudited)
Revenues	$	783,217	$	767,897
Net income	$	86,844	$	82,762

Earnings per share:
Basic	$	1.66	$	1.60

Diluted	$	1.65	$	1.58

Hydralyte

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Care Pharma

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

Goodwill (Tables)

12 Months Ended

Mar. 31, 2015

Goodwill [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2013, 2014, and 2015:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2012
Goodwill	$	296,483		$	—		$	72,549		$	369,032
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2012	166,313			—			7,389			173,702

2013 additions	226			—			—			226
2013 reductions	(6,382		)	—			—			(6,382		)

Balance – March 31, 2013
Goodwill	290,327			—			72,549			362,876
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2013	160,157			—			7,389			167,546

2014 additions	—			23,122			—			23,122
Effects of foreign currency exchange rates	—			243			—			243

Balance – March 31, 2014
Goodwill	290,327			23,365			72,549			386,241
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015
Goodwill	393,581			20,440			71,960			485,981
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2015	$	263,411		$	20,440		$	6,800		$	290,651

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2015

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2013, 2014, and 2015 is as follows:



(In thousands)	Year Ended March 31, 2013
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2012	$	1,245,414		$	217,512		$	158	$	1,463,084
Reclassifications	(1,696		)	1,696			—		—
Reductions	—			(16,142		)	—		(16,142		)
Balance – March 31, 2013	$	1,243,718		$	203,066		$	158	$	1,446,942

Accumulated Amortization
Balance – March 31, 2012	$	—		$	62,404		$	158	$	62,562
Additions	—			11,678			—		11,678
Reductions	—			(538		)	—		(538		)
Balance – March 31, 2013	$	—		$	73,544		$	158	$	73,702

Intangibles, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,898		$	101,611		$	—	$	1,225,509
International OTC Healthcare	—			—			—		—
Household Cleaning	119,820			27,911			—		147,731
Intangible assets, net – March 31, 2013	$	1,243,718		$	129,522		$	—	$	1,373,240



(In thousands)	Year Ended March 31, 2014
	Indefinite Lived Trademarks		Finite Lived Trademarks		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	$	—	$	83,801	$	—		$	83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,897	$	93,242	$	—		$	1,217,139
International OTC Healthcare	30,161		1,530		—			31,691
Household Cleaning	119,820		26,167		—			145,987
Intangible assets, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817



(In thousands)	Year Ended March 31, 2015
	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	—	$	1,478,618
Additions	673,180			124,774			—		797,954
Reclassifications	(46,506		)	46,506			—		—
Reductions	(9,548		)	(17,674		)	—		(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	—		(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	—	$	83,801
Additions	—			12,995			—		12,995
Effects of foreign currency exchange rates	—			(26		)	—		(26		)
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	—	$	1,912,633
International OTC Healthcare	86,141			1,231			—		87,372
Household Cleaning	110,272			24,423			—		134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

Schedule of Expected Amortization Expense

At March 31, 2015, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2016	17,868
2017	17,868
2018	17,868
2019	17,868
2020	17,868
Thereafter	171,956
	$	261,296

Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2015			March 31, 2014
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	217,500			287,500
2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	660,000			—
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
	1,593,600			937,500
Current portion of long-term debt	—			—
	1,593,600			937,500
Less: unamortized discount	(4,889		)	(3,086		)
Long-term debt, net of unamortized discount	$	1,588,711		$	934,414

Aggregate Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2016	$	—
2017	66,100
2018	—
2019	217,500
2020	250,000
Thereafter	1,060,000
	$	1,593,600

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value

Vested and Nonvested at March 31, 2012	363.4		$	9.92

Granted	128.9		13.59
Vested and issued	(58.7	)	9.99
Forfeited	(12.3	)	10.69
Vested and nonvested at March 31, 2013	421.3		11.01
Vested at March 31, 2013	70.4		8.52

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Stock Options, Valuation Assumptions



	Year Ended March 31,
	2015		2014
Expected volatility	47.3	%	48.0	%
Expected dividends	—		—
Expected term in years	6.0		6.0
Risk-free rate	2.2	%	1.3	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2012	1,745.4		$	8.44

Granted	444.9		13.36
Exercised	(786.5	)	7.67
Forfeited or expired	(17.4	)	11.21
Outstanding at March 31, 2013	1,386.4		10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40		7.7	$	16,978
Exercisable at March 31, 2015	312.3		15.15		6.4	8,664

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income from Continuing Operations Before Income Taxes, Domestic and Foreign

Income from continuing operations before income taxes consists of the following:



	Year Ended March 31,
	2015		2014		2013
(In thousands)
United States	$	122,588	$	98,786	$	105,727
Foreign	4,870		2,962		307
	$	127,458	$	101,748	$	106,034

Components of Provision for Income Taxes

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2015			2014			2013
Current
Federal	$	13,066		$	7,801		$	12,520
State	760			625			1,972
Foreign	3,228			1,675			532
Deferred
Federal	31,012			27,045			23,845
State	1,162			(7,879		)	1,660
Foreign	(30		)	(134		)	—
Total provision for income taxes	$	49,198		$	29,133		$	40,529

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2015			2014
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	4,106		$	4,082
Inventory capitalization	1,550			1,301
Inventory reserves	1,495			362
Net operating loss carryforwards	23,800			327
State income taxes	7,557			3,728
Accrued liabilities	619			642
Stock compensation	3,517			2,358
Other	834			702
Total deferred tax assets	43,478			13,502

Deferred Tax Liabilities
Property and equipment	(1,143		)	(1,467		)
Intangible assets	(385,807		)	(218,696		)
Total deferred tax liabilities	(386,950		)	(220,163		)

Net deferred tax liability	$	(343,472	)	$	(206,661	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
(In thousands)	2015					2014					2013
				%					%					%
Income tax provision at statutory rate	$	44,610		35.0		$	35,612		35.0		$	37,112		35.0
Foreign tax (benefit) provision	(2,019		)	(1.6	)	(918		)	(0.9	)	—			—
State income taxes, net of federal income tax benefit	2,865			2.3		2,004			2.0		3,413			3.2
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	—			—		(8,892		)	(8.7	)	(1,741		)	(1.6	)
Goodwill impairment	206			0.2		—			—		—			—
Transaction costs	2,936			2.3		—			—		—			—
Nondeductible compensation	566			0.4		1,011			1.0		1,684			1.6
Other	34			—		316			0.3		61			—
Total provision for income taxes	$	49,198		38.6		$	29,133		28.7		$	40,529		38.2

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2015			2014			2013
(In thousands)
Balance – beginning of year	$	1,236		1,016			292
Additions based on tax positions related to the current year	2,229			360			831
Reductions based on lapse of statute of limitations	(45		)	(140		)	(107		)
Balance – end of year	$	3,420		$	1,236		$	1,016

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2016	$	1,612	$	311	$	1,923
2017	1,772		77		1,849
2018	1,856		—		1,856
2019	1,864		—		1,864
2020	2,465		—		2,465
	$	9,569	$	388	$	9,957

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.4 million due in the future under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2015			2014
Minimum lease payments	$	9,957		$	4,621
Less: Sublease rentals	(1,401		)	—
	$	8,556		$	4,621

Unrecorded Unconditional Purchase Obligations



(In thousands)
Year Ending March 31,
2016	1,074
2017	1,044
2018	1,013
2019	982
2020	560
Thereafter	—
	$	4,673

Business Segments (Tables)

12 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The table below summarizes information about our operating and reportable segments.



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	566,256		$	61,116	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	562,869			61,116		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	563,506			61,180		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	346,725			38,360		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	259,828		$	27,438	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	482,138		$	29,872	$	83,629	$	595,639
Elimination of intersegment revenues	(3,185		)	—		—		(3,185		)
Third-party segment revenues	478,953			29,872		83,629		592,454
Other revenues	749			42		4,136		4,927
Total segment revenues	479,702			29,914		87,765		597,381
Cost of sales	184,796			12,646		64,388		261,830
Gross profit	294,906			17,268		23,377		335,551
Advertising and promotion	77,083			5,264		2,621		84,968
Contribution margin	$	217,823		$	12,004	$	20,756	250,583
Other operating expenses								61,967
Operating income								188,616
Other expense								86,868
Income before income taxes								101,748
Provision for income taxes								29,133
Net income								$	72,615



	Year Ended March 31, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	519,046	$	14,493	$	83,376	$	616,915
Elimination of intersegment revenues	—		—		—		—
Third-party segment revenues	519,046		14,493		83,376		616,915
Other revenues	639		45		2,519		3,203
Total segment revenues	519,685		14,538		85,895		620,118
Cost of sales	205,389		6,265		64,727		276,381
Gross profit	314,296		8,273		21,168		343,737
Advertising and promotion	80,051		1,643		5,457		87,151
Contribution margin	$	234,245	$	6,630	$	15,711	256,586
Other operating expenses							64,702
Operating income							191,884
Other expense							85,850
Income before income taxes							106,034
Provision for income taxes							40,529
Net income							$	65,505

Information about our Revenues from Similar Product Groups



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	81,849		16,076		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	563,506	$	61,180	$	89,937	$	714,623



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	108,101	$	1,883	$	—	$	109,984
Cough & Cold	100,060		13,365		—		113,425
Women's Health	1,960		1,835		—		3,795
Gastrointestinal	81,469		838		—		82,307
Eye & Ear Care	75,568		9,923		—		85,491
Dermatologicals	56,436		1,655		—		58,091
Oral Care	47,900		413		—		48,313
Other OTC	8,208		2		—		8,210
Household Cleaning	—		—		87,765		87,765
Total segment revenues	$	479,702	$	29,914	$	87,765	$	597,381



	Year Ended March 31, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	107,272	$	245	$	—	$	107,517
Cough & Cold	121,514		4,277		—		125,791
Women's Health	2,544		—		—		2,544
Gastrointestinal	97,536		82		—		97,618
Eye & Ear Care	76,960		9,116		—		86,076
Dermatologicals	56,114		399		—		56,513
Oral Care	49,002		419		—		49,421
Other OTC	8,743		—		—		8,743
Household Cleaning	—		—		85,895		85,895
Total segment revenues	$	519,685	$	14,538	$	85,895	$	620,118

Allocation of Long-Term Assets to Segments

These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	20,440	$	6,800	$	290,651

Intangible assets
Indefinite-lived	1,676,991		86,141		110,272		1,873,404
Finite-lived	235,642		1,231		24,423		261,296
Intangible assets, net	1,912,633		87,372		134,695		2,134,700
Total	$	2,176,044	$	107,812	$	141,495	$	2,425,351

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2015 and 2014 is as follows:

Year Ended March 31, 2015



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2014		September 30, 2014			December 31, 2014			March 31, 2015
Total revenues	$	145,702	$	181,269		$	197,606		$	190,046
Cost of sales (exclusive of depreciation shown below)	63,836		78,727			85,861			79,976
Gross profit	81,866		102,542			111,745			110,070

Operating expenses
Advertising and promotion	19,096		25,044			30,144			25,367
General and administrative	17,006		27,128			19,454			17,685
Depreciation and amortization	2,961		3,852			5,154			5,773
	39,063		56,024			54,752			48,825
Operating income	42,803		46,518			56,993			61,245
Net interest expense	14,653		18,193			24,592			23,796
Gain on sale of asset	—		—			(1,133		)	—
Income before income taxes	28,150		28,325			33,534			37,449
Provision for income taxes	11,418		11,862			12,241			13,677
Net income	$	16,732	$	16,463		$	21,293		$	23,772


Earnings per share:
Basic	$	0.32	$	0.32		$	0.41		$	0.45
Diluted	$	0.32	$	0.31		$	0.40		$	0.45

Weighted average shares outstanding:
Basic	51,956		52,088			52,278			52,356
Diluted	52,533		52,594			52,730			52,821

Comprehensive income, net of tax:
Currency translation adjustments	2,726		(10,830		)	(8,779		)	(7,268		)
Total other comprehensive income (loss)	2,726		(10,830		)	(8,779		)	(7,268		)
Comprehensive income	$	19,458	$	5,633		$	12,514		$	16,504

Year Ended March 31, 2014



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2013		September 30, 2013		December 31, 2013			March 31, 2014
Total revenues	$	142,512	$	166,945	$	144,871		$	143,053
Cost of sales (exclusive of depreciation shown below)	59,488		73,723		64,403			64,216
Gross profit	83,024		93,222		80,468			78,837

Operating expenses
Advertising and promotion	18,681		24,547		24,229			17,511
General and administrative	11,634		11,619		12,137			13,091
Depreciation and amortization	3,268		3,294		3,644			3,280
	33,583		39,460		40,010			33,882
Operating income	49,441		53,762		40,458			44,955
Net interest expense	15,905		16,439		21,260			14,978
Loss on extinguishment of debt	—		—		15,012			3,274
Income before income taxes	33,536		37,323		4,186			26,703
Provision for income taxes	12,844		4,531		1,056			10,702
Net income (loss)	$	20,692	$	32,792	$	3,130		$	16,001

Earnings per share:
Basic	$	0.40	$	0.64	$	0.06		$	0.31
Diluted	$	0.40	$	0.63	$	0.06		$	0.30

Weighted average shares outstanding:
Basic	51,222		51,463		51,806			51,893
Diluted	52,040		52,219		52,445			52,513

Comprehensive income, net of tax:
Currency translation adjustments	1		1,122		(2,694		)	2,414
Total other comprehensive income (loss)	1		1,122		(2,694		)	2,414
Comprehensive income	$	20,693	$	33,914	$	436		$	18,415

Condensed Consolidating Financial Statements (Tables)

12 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	97,509		$	474,338		$	23,286		$	(2,679	)	$	592,454
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total revenues	—			97,804			479,224			24,925			(4,572		)	597,381

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			60,532			260,532			15,497			(1,010		)	335,551

Advertising and promotion	—			10,223			69,583			5,162			—			84,968
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			18,826			113,767			8,208			—			146,935
Operating income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868
Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748
Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	102,203		$	510,041		$	4,671		$	—		$	616,915
Other revenues	—			278			3,158			1,517			(1,750		)	3,203
Total revenues	—			102,481			513,199			6,188			(1,750		)	620,118

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,333			236,795			2,003			(1,750		)	276,381
Gross profit	—			63,148			276,404			4,185			—			343,737

Advertising and promotion	—			12,102			73,623			1,426			—			87,151
General and administrative	5,127			6,917			38,713			710			—			51,467
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Total operating expenses	6,473			19,588			123,597			2,195			—			151,853
Operating (loss) income	(6,473		)	43,560			152,807			1,990			—			191,884

Other (income) expense
Interest income	(30,561		)	(57,496		)	—			(1		)	88,045			(13		)
Interest expense	34,671			84,420			53,374			—			(88,045		)	84,420
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Total other expense (income)	(68,185		)	(37,417		)	51,892			(1		)	139,561			85,850
Income (loss) before income taxes	61,712			80,977			100,915			1,991			(139,561		)	106,034
Provision (benefit) for income taxes	(3,793		)	5,807			38,006			509			—			40,529
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505

Comprehensive income, net of tax:
Currency translation adjustments	(91		)	—			—			(91		)	91			(91		)
Total other comprehensive (loss) income	(91		)	—			—			(91		)	91			(91		)
Comprehensive income (loss)	$	65,414		$	75,170		$	62,909		$	1,391		$	(139,470	)	$	65,414

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			28,603			—			—			—			28,603
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,146,720		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,669,405

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized discount	—			(4,889		)	—			—			—			(4,889		)
Long-term debt, net of unamortized discount	—			1,588,711			—			—			—			1,588,711

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,668,924			1,633,323			77,274			(4,494,004		)	2,041,781

Stockholders' Equity
Common stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost - 266 shares	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders' Equity	$	2,783,888		$	4,146,720		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,669,405

Condensed Consolidating Balance Sheet

March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185

Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358

Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414

Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303

Stockholders' Equity
Common Stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders’ Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long term income taxes payable	—			—			2,294			—			—			2,294
Amortization of deferred financing costs	—			6,735			—			—			—			6,735
Stock-based compensation costs	6,918			—			—			—			—			6,918
Amortization of debt discount	—			2,086			—			—			—			2,086
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from sale of business	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effects of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of deferred financing costs	—			7,102			—			—			—			7,102
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment on 2010 Senior Notes	—			(15,527		)	—			—			—			(15,527		)
Amortization of debt discount	—			3,410			—			—			—			3,410
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash used in investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Term loan repayments	—			(157,500		)	—			—			—			(157,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayment under revolving credit agreement	—			(83,000		)	—			—			—			(83,000		)
Payment of deferred financing costs	—			(7,466		)	—			—			—			(7,466		)
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	65,505		$	75,170		$	62,909		$	1,482		$	(139,561	)	$	65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,346			569			11,261			59			—			13,235
Deferred income taxes	138			4,341			21,036			(10		)	—			25,505
Amortization of deferred financing costs	—			9,832			—			—			—			9,832
Stock-based compensation costs	3,772			—			—			—			—			3,772
Loss on extinguishment of debt	—			1,443			—			—			—			1,443
Amortization of debt discount	—			4,632			—			—			—			4,632
Lease termination costs	975			—			—			—			—			975
Loss on disposal of equipment	82			—			21			—			—			103
Equity in income of subsidiaries	(72,295		)	(65,784		)	(1,482		)	—			139,561			—
Changes in operating assets and liabilities
Accounts receivable	4			(373		)	(12,391		)	(122		)	—			(12,882		)
Inventories	—			(3,066		)	(6,360		)	84			—			(9,342		)
Prepaid expenses and other current assets	3,160			(37		)	(135		)	108			—			3,096
Accounts payable	(1,930		)	5,784			20,687			136			—			24,677
Accrued liabilities	(39		)	2			7,069			22			—			7,054
Net cash provided by operating activities	718			32,513			102,615			1,759			—			137,605

Investing Activities
Purchases of property and equipment	(10,268		)	—			—			—			—			(10,268		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of brands from GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash provided by (used in) investing activities	(10,494		)	—			21,715			—			—			11,221

Financing Activities
Term loan repayments	—			(190,000		)	—			—			—			(190,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Repayments under revolving credit agreement	—			(15,000		)	—			—			—			(15,000		)
Payment of deferred financing costs	—			(1,146		)	—			—			—			(1,146		)
Proceeds from exercise of stock options	6,029			—			—			—			—			6,029
Intercompany activity, net	246			125,633			(124,330		)	(1,549		)	—			—
Net cash (used in) provided by financing activities	6,275			(32,513		)	(124,330		)	(1,549		)	—			(152,117		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(54		)	—			(54		)
(Decrease) increase in cash and cash equivalents	(3,501		)	—			—			156			—			(3,345		)
Cash and cash equivalents - beginning of year	18,221			—			—			794			—			19,015
Cash and cash equivalents - end of year	$	14,720		$	—		$	—		$	950		$	—		$	15,670

Acquisitions (Narrative) (Details) (USD $)	0 Months Ended	12 Months Ended					0 Months Ended	12 Months Ended						0 Months Ended	12 Months Ended
Acquisitions (Narrative) (Details) (USD $)	Sep. 03, 2014 brand	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Sep. 03, 2014	Mar. 31, 2012	Sep. 03, 2014 Insight Pharmaceuticals Corporation brand	Mar. 31, 2015 Insight Pharmaceuticals Corporation	Sep. 03, 2014 Insight Pharmaceuticals Corporation	Sep. 03, 2014 Insight Pharmaceuticals Corporation Intangible assets	Sep. 03, 2014 Insight Pharmaceuticals Corporation Inventory	Sep. 03, 2014 Insight Pharmaceuticals Corporation Property, plant and equipment	Apr. 30, 2014 Hydralyte	Jul. 01, 2013 Care Pharma	Mar. 31, 2015 Care Pharma	Jul. 01, 2013 Care Pharma
Business Acquisition [Line Items]
Purchase price, gross							$ 753,200,000
Number of brands acquired							27
Number of brands sold	1						1
Indefinite-lived intangible assets									599,600,000							29,800,000
Finite-lived intangible assets									124,800,000							1,700,000
Purchased amortizable intangible assets, weighted average useful life							16 years 2 months 12 days							15 years 1 month 6 days
Finite-lived intangible assets, weighted average remaining period		14 years 7 months 6 days						15 years 7 months 12 days							11 years 9 months 0 days
Goodwill		290,651,000	190,911,000	167,546,000		173,702,000			103,255,000				1,224,000			23,122,000
Gross segment revenues		713,457,000	595,639,000	616,915,000				97,100,000
Assets sold on acquisition date, not included in consideration transferred									18,500,000	17,700,000	600,000	200,000
Indefinite-lived intangible assets acquired					$ 17,700,000				$ 724,374,000				$ 73,580,000			$ 31,502,000

Acquisitions (Allocations) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Sep. 03, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Sep. 03, 2014 Insight Pharmaceuticals Corporation	Apr. 30, 2014 Hydralyte	Jul. 01, 2013 Care Pharma
Purchase Price
Cash acquired						$ 3,507		$ 1,546
Accounts receivable						25,784		1,658
Inventories						23,559	1,970	2,465
Deferred income tax assets						860		283
Prepaids and other current assets						1,407		647
Property, plant and equipment						2,308	1,267	163
Goodwill	290,651		190,911	167,546	173,702	103,255	1,224	23,122
Intangible assets		17,700				724,374	73,580	31,502
Total assets acquired						885,054	78,041	61,386
Accounts payable						16,079		1,537
Accrued expenses						8,003	38	2,788
Deferred income tax liabilities - long term						107,799
Other long term liabilities							12	300
Total liabilities assumed						131,881	50	4,625
Net assets acquired						$ 753,173	$ 77,991	$ 56,761

Acquisitions (Pro Forma) (Details) (Insight Pharmaceuticals Corporation, USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Insight Pharmaceuticals Corporation
Pro Forma Information
Revenues	$ 783,217	$ 767,897
Net income	$ 86,844	$ 82,762
Basic (USD per share)	$ 1.66	$ 1.60
Diluted (USD per share)	$ 1.65	$ 1.58

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 97,764	$ 74,992
Less allowances for discounts, returns and uncollectible accounts	(9,906)	(9,942)
Accounts receivable, net	87,858	65,050
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	95,411	73,632
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 2,353	$ 1,360

Inventories (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 7,588,000	$ 3,099,000
Finished goods	66,412,000	62,487,000
Inventories	74,000,000	65,586,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,100,000	$ 1,100,000

Property and Equipment (Details) (USD $)	12 Months Ended
Property and Equipment (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Components of Property and Equipment
Property and equipment, gross	$ 25,700,000	$ 17,442,000
Accumulated depreciation	(11,956,000)	(7,845,000)
Property and equipment, net	13,744,000	9,597,000
Depreciation expense	3,800,000	3,200,000	1,600,000
Machinery
Components of Property and Equipment
Property and equipment, gross	4,743,000	1,927,000
Computer equipment
Components of Property and Equipment
Property and equipment, gross	11,339,000	8,923,000
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,484,000	1,858,000
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,134,000	$ 4,734,000

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 386,241	$ 362,876	$ 369,032
Goodwill, net, beginning	190,911	167,546	173,702
Accumulated impairment losses	(195,330)	(195,330)	(195,330)	(195,330)
Additions	104,478	23,122	226
Reductions	(589)		(6,382)
Effects of foreign currency exchange rates	(4,149)	243
Goodwill, gross, ending	485,981	386,241	362,876
Goodwill, net, ending	290,651	190,911	167,546
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	290,327	290,327	296,483
Goodwill, net, beginning	160,157	160,157	166,313
Accumulated impairment losses	(130,170)	(130,170)	(130,170)	(130,170)
Additions	103,254	0	226
Reductions	0		(6,382)
Effects of foreign currency exchange rates	0	0
Goodwill, gross, ending	393,581	290,327	290,327
Goodwill, net, ending	263,411	160,157	160,157
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	23,365	0	0
Goodwill, net, beginning	23,365	0	0
Accumulated impairment losses	0	0	0	0
Additions	1,224	23,122	0
Reductions	0		0
Effects of foreign currency exchange rates	(4,149)	243
Goodwill, gross, ending	20,440	23,365	0
Goodwill, net, ending	20,440	23,365	0
Household Cleaning
Goodwill [Roll Forward]
Goodwill, gross, beginning	72,549	72,549	72,549
Goodwill, net, beginning	7,389	7,389	7,389
Accumulated impairment losses	(65,160)	(65,160)	(65,160)	(65,160)
Additions	0	0	0
Reductions	(589)		0
Effects of foreign currency exchange rates	0	0
Goodwill, gross, ending	71,960	72,549	72,549
Goodwill, net, ending	$ 6,800	$ 7,389	$ 7,389

Goodwill (Narrative) (Details) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended				12 Months Ended				0 Months Ended		3 Months Ended
Goodwill (Narrative) (Details) (USD $)	Mar. 31, 2015 acquisition	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2014 Comet Brand	Mar. 31, 2015 North American OTC Healthcare	Mar. 31, 2014 North American OTC Healthcare	Mar. 31, 2013 North American OTC Healthcare	Mar. 31, 2012 North American OTC Healthcare	Mar. 31, 2015 International OTC Healthcare	Mar. 31, 2014 International OTC Healthcare	Mar. 31, 2013 International OTC Healthcare	Mar. 31, 2012 International OTC Healthcare	Oct. 31, 2012 Phazyme	Oct. 31, 2012 Phazyme	Jun. 30, 2012 GSK Brands	Jul. 01, 2013 Care Pharma
Goodwill [Line Items]
Goodwill, post-closing inventory and apportionment adjustment																$ 200,000
Goodwill acquired during period	104,478,000	23,122,000	226,000			103,254,000	0	226,000		1,224,000	23,122,000	0
Brand divested, sale price															22,300,000
Reduction in goodwill														6,400,000
Goodwill	290,651,000	190,911,000	167,546,000	173,702,000		263,411,000	160,157,000	160,157,000	166,313,000	20,440,000	23,365,000	0	0				23,122,000
Number of business acquisitions	2
Gain on sale of intangible assets					1,100,000
Goodwill impairment charge	$ 0	$ 0
Reporting unit, fair value in excess of carrying amount (percent)	45.20%
Reporting unit, fair value in excess of carrying amount, minimum (percent)	10.00%					10.00%

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	$ 261,296
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	1,873,404
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	12,995	10,256	11,678
Intangible Assets, Accumulated Amortization, Written off Related to Sale of Business Unit		(158)	(538)
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates	(26)	(1)
Intangible Assets, Net Reclassification	0
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning	1,478,618	1,446,942	1,463,084
Intangible assets, additions, gross	797,954	31,502	0
Intangible assets, reductions or disposals, gross	(27,222)	(158)	(16,142)
Intangible assets, Effects of foreign currency exchange rates	(17,880)	332
Intangible assets, gross, ending	2,231,470	1,478,618	1,446,942
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, beginning	83,801	73,702	62,562
Intangible assets, accumulated amortization, additions	12,995	10,256	11,678
Intangible assets, accumulated amortization, ending	96,770	83,801	73,702
Intangible assets, net	2,134,700	1,394,817	1,373,240
North American OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	235,642
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	1,676,991
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, net	1,912,633	1,217,139	1,225,509
International OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	1,231
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	86,141
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, net	87,372	31,691	0
Household Cleaning
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	24,423
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	110,272
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, net	134,695	145,987	147,731
Finite Lived Trademarks
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	261,296	120,939	129,522
Finite-lived Intangible Assets, Accumulated Amortization, Written off Related to Sale of Business Unit		0	(538)
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning	204,740	203,066	217,512
Finite-lived intangibles, additions, gross	124,774	1,657	1,696
Finite-lived intangibles, reclassifications	46,506
Finite-lived intangibles, reductions or disposals, gross	(17,674)	0	(16,142)
Finite-lived intangibles, Effects of foreign currency exchange rates	(280)	17
Finite-lived intangibles, gross, ending	358,066	204,740	203,066
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	83,801	73,544	62,404
Intangible assets, accumulated amortization, additions	12,995	10,256	11,678
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates	(26)	(1)
Finite-lived intangibles, accumulated amortization, ending	96,770	83,801	73,544
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	12,995	10,256	11,678
Finite Lived Trademarks \| North American OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	235,642	93,242	101,611
Finite Lived Trademarks \| International OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	1,231	1,530	0
Finite Lived Trademarks \| Household Cleaning
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	24,423	26,167	27,911
Noncompete Agreements
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	0	0	0
Finite-lived Intangible Assets, Accumulated Amortization, Written off Related to Sale of Business Unit		(158)	0
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning	0	158	158
Finite-lived intangibles, additions, gross	0	0	0
Finite-lived intangibles, reclassifications	0
Finite-lived intangibles, reductions or disposals, gross	0	(158)	0
Finite-lived intangibles, Effects of foreign currency exchange rates	0	0
Finite-lived intangibles, gross, ending	0	0	158
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	0	158	158
Intangible assets, accumulated amortization, additions	0	0	0
Finite-lived intangibles, accumulated amortization, Effects of foreign currency exchange rates	0	0
Finite-lived intangibles, accumulated amortization, ending	0	0	158
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	0	0	0
Noncompete Agreements \| North American OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	0	0	0
Noncompete Agreements \| International OTC Healthcare
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	0	0	0
Noncompete Agreements \| Household Cleaning
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles	0	0	0
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,273,878	1,243,718	1,245,414
Indefinite-lived intangibles, additions	673,180	29,845	(1,696)
Indefinite-lived intangibles, reclassifications	(46,506)
Indefinite-lived intangibles, reductions	(9,548)	0	0
Indefinite-lived intangibles, Effects of foreign currency exchange rates	(17,600)	315
Indefinite-lived intangibles, ending	1,873,404	1,273,878	1,243,718
Indefinite Lived Trademarks \| North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	1,676,991	1,123,897	1,123,898
Indefinite Lived Trademarks \| International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	86,141	30,161	0
Indefinite Lived Trademarks \| Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending	$ 110,272	$ 119,820	$ 119,820

Intangible Assets (Narrative) (Details) (USD $)	0 Months Ended		12 Months Ended						12 Months Ended				12 Months Ended				0 Months Ended	12 Months Ended				0 Months Ended	1 Months Ended		12 Months Ended			0 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Sep. 03, 2014 brand	Oct. 31, 2012	Mar. 31, 2015 acquisition	Mar. 31, 2014	Mar. 31, 2013	Sep. 03, 2014	Mar. 31, 2015 North American OTC Healthcare	Mar. 31, 2015 Household Cleaning	Mar. 31, 2015 Minimum	Mar. 31, 2015 Maximum	Mar. 31, 2015 Indefinite-lived intangible assets trade_name	Mar. 31, 2015 Trade names trade_name	Mar. 31, 2015 Debrox	Mar. 31, 2015 New Skin	Mar. 31, 2015 Ecotrin	Mar. 31, 2015 Ecotrin Minimum	Feb. 28, 2015 Pediacare trade name	Mar. 31, 2015 Pediacare trade name	Mar. 31, 2015 Finite Lived Trademarks	Mar. 31, 2014 Finite Lived Trademarks	Mar. 31, 2013 Finite Lived Trademarks	Mar. 31, 2015 Comet Brand	Dec. 31, 2014 Comet Brand	Oct. 31, 2012 Phazyme	Mar. 31, 2013 GSK Brands Finite Lived Trademarks	Mar. 31, 2014 Care Pharma	Jul. 01, 2013 Care Pharma	Sep. 03, 2014 Insight Pharmaceuticals Corporation brand	Sep. 03, 2014 Insight Pharmaceuticals Corporation	Apr. 30, 2014 Hydralyte
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives									10 years	30 years							20 years	20 years
Intangible assets acquired during period			$ 797,954,000	$ 31,502,000	$ 0																					$ 31,500,000
Brand divested, sale price																								22,300,000
Intangible assets, reductions, net		15,600,000
Finite-lived intangibles, additions, gross																			124,774,000	1,657,000	1,696,000				1,696,000
Number of business acquisitions			2
Intangible assets acquired						17,700,000																					31,502,000		724,374,000	73,580,000
Number of brands sold	1																											1
Impairment of intangible assets			0
Reporting unit, fair value in excess of carrying amount (percent)			45.20%										8.30%	9.20%	7.90%
Reporting unit, fair value in excess of carrying amount, minimum (percent)			10.00%				10.00%	10.00%
Number of indefinite-lived trade names											0	3
Reporitng unit, fair value in excess of carrying amount, maximum (percent)												10.00%
Reporting unit, amount of fair value in excess of carrying amount													76,300,000	37,200,000	32,900,000
Proceeds from early buy-out of intangible assets																							10,000,000
Gain on sale of intangible assets																							1,100,000
Sale of intangible assets, quarterly payments																						$ 1,000,000
Discount rate													10.00%	10.00%	10.00%
Increase (decrease) in projected long-term non-GAAP net income (percent)													(7.70%)	(8.40%)		(7.30%)
Increase (decrease) in discount rate													0.62%	0.77%	0.72%

Intangible Assets (Expected Amortization Expense) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted average remaining period	14 years 7 months 6 days
Amortization of intangible assets	$ 12,995	$ 10,256	$ 11,678
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2016	17,868
2017	17,868
2018	17,868
2019	17,868
2020	17,868
Thereafter	171,956
Intangible assets, net	$ 261,296
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Payables and Accruals [Abstract]
Accrued marketing costs	$ 16,903	$ 11,812
Accrued compensation costs	8,840	6,232
Accrued broker commissions	1,134	1,019
Income taxes payable	2,642	1,854
Accrued professional fees	2,769	2,002
Deferred rent	1,021	1,258
Accrued production costs	5,610	1,506
Accrued lease termination costs	669	0
Other accrued liabilities	1,360	763
Total other accrued liabilities	$ 40,948	$ 26,446

Long-Term Debt (Narrative 2012 Senior Notes) (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,593,600,000	$ 937,500,000
Percentage of subsidiary owned			100.00%	100.00%
2012 Senior Notes
Debt Instrument [Line Items]
Debt issuance costs capitalized				12,600,000
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000,000	250,000,000
Debt instrument, face amount	$ 250,000,000.0
Debt instrument, stated interest rate	8.125%

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)	3 Months Ended				12 Months Ended						3 Months Ended		0 Months Ended	12 Months Ended					0 Months Ended		38 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended			0 Months Ended						0 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Dec. 17, 2013	Jan. 31, 2012	Jan. 31, 2012 Term Loan and ABL Revolver 2012	Mar. 31, 2013 Term Loans Amended 2012 Term Loan	Sep. 03, 2014 Term Loans Amended 2 2012 Term Loan [Member]	Jan. 31, 2012 Term Loans 2012 Term Loan	Mar. 31, 2015 Term Loans 2012 Term Loan	Sep. 03, 2014 Term Loans 2012 Term Loan	Jan. 31, 2012 Term Loans 2012 Term Loan	Sep. 03, 2014 2012 Term B-2 Loan Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 Revolving Credit Facility 2012 ABL Revolver, Amendment 3	Mar. 31, 2015 Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Mar. 31, 2015 Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Feb. 21, 2013 LIBOR Term Loans Amended 2012 Term Loan	Feb. 21, 2013 LIBOR Term Loans Amended 2012 Term Loan	Sep. 03, 2014 LIBOR Term Loans Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 LIBOR Term Loans 2012 Term Loan	Sep. 03, 2014 LIBOR 2012 Term B-2 Loan Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 LIBOR 2012 Term B-2 Loan Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 LIBOR Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 LIBOR Minimum Term Loans 2012 Term Loan	Sep. 03, 2014 LIBOR Minimum Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 LIBOR Maximum Revolving Credit Facility 2012 ABL Revolver	Feb. 21, 2013 Base Rate Term Loans Amended 2012 Term Loan	Sep. 03, 2014 Base Rate Term Loans Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 Base Rate Term Loans 2012 Term Loan	Sep. 03, 2014 Base Rate 2012 Term B-2 Loan Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 Base Rate 2012 Term B-2 Loan Amended 2 2012 Term Loan [Member]	Sep. 03, 2014 Base Rate Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 Base Rate Minimum Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 Base Rate Maximum Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 Federal Funds Rate Term Loans 2012 Term Loan	Sep. 03, 2014 Federal Funds Rate Revolving Credit Facility 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, face amount																$ 660,000,000.0	$ 720,000,000.0
Debt instrument, term													7 years							5 years
Revolving credit facility, increase in borrowing capacity																		40,000,000			85,000,000
Line of credit facility, maximum borrowing capacity																					135,000,000	50,000,000.0
Debt Instrument, Interest Rate, Increase (Decrease)																					0.25%
Debt instrument, discount, percentage																1.50%
Proceeds from issuance of long-term debt													650,100,000
Debt issuance costs capitalized										20,600,000
Percentage of subsidiary owned								100.00%	100.00%
Debt instrument, basis spread on variable rate (percent)																							2.75%		3.125%		3.50%			1.00%
Debt Instrument, Interest Rate During Period														5.30%
Quarterly payment, percent of original principal amount															0.25%
Debt instrument, reference rate floor												1.00%												1.00%				1.00%					2.00%	2.00%			2.00%
Interest rate, contingent margin step-down per annum (percent)																																				3.25%
Loss on extinguishment of debt	$ 3,274,000	$ 15,012,000	$ 0	$ 0	$ 0	$ 18,286,000	$ 1,443,000				$ 1,400,000
Debt instrument, basis spread on variable rate, fixed component																										1.00%			1.00%						2.00%						0.50%	0.50%
Debt instrument, variable rate																													1.75%									0.75%
Debt instrument, conditional variable rate																															2.00%	2.25%							1.00%	1.25%
Line of credit facility, commitment fee percentage																				0.50%
Line of credit facility, conditional commitment fee percentage																			0.375%
Line of credit facility, interest rate at period end																					2.80%

Long-Term Debt (Narrative 2013 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 400,000,000.0
Debt instrument, stated interest rate	5.375%
Debt issuance costs capitalized	$ 7,200,000

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) (USD $)											12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015 Senior Notes 2012 Senior Notes	Mar. 31, 2015 Senior Notes 2013 Senior Notes	Mar. 31, 2015 Term Loans 2012 Term Loan	Jan. 31, 2012 Prior to February 1, 2016 [Member] Senior Notes 2012 Senior Notes	Jan. 31, 2012 Prior to February 1, 2015 [Member] Senior Notes 2012 Senior Notes	Jan. 31, 2012 Upon Change in Control Senior Notes 2012 Senior Notes	Mar. 31, 2015 Prior to December 15, 2016 [Member] Senior Notes 2013 Senior Notes	Mar. 31, 2015 On Or After December 15, 2016 [Member] Senior Notes 2013 Senior Notes	Mar. 31, 2015 Revolving Credit Facility 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount				101.00%		100.00%	108.125%	101.00%	100.00%	105.375%
Debt instrument, percentage of principal amount eligible for redemption							35.00%		35.00%
Unamortized debt issuance expense	$ 28,600,000
Debt instrument, unamortized discount	4,889,000	3,086,000
Debt instrument, unamortized debt issuance expense and discount			8,700,000	6,200,000	17,400,000						1,200,000
Repayments of long-term debt											66,100,000
Revolving credit facility, remaining borrowing capacity											$ 44,900,000

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,593,600	$ 937,500
Current portion of long-term debt	0	0
Long-term debt, gross, excluding current maturities	1,593,600	937,500
Less: unamortized discount	(4,889)	(3,086)
Long-term debt, net of unamortized discount	1,588,711	934,414
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	400,000	400,000
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000	250,000
Term Loans \| 2012 Term B-1 Loan
Debt Instrument [Line Items]
Long-term debt, gross	217,500	287,500
Term Loans \| 2012 Term B-2 Loan
Debt Instrument [Line Items]
Long-term debt, gross	660,000	0
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt, gross	$ 66,100	$ 0

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Debt Disclosure [Abstract]
2016	$ 0
2017	66,100
2018	0
2019	217,500
2020	250,000
Thereafter	1,060,000
Aggregate future principal payments	$ 1,593,600	$ 937,500

Fair Value Measurements (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	$ 1,593,600,000	$ 937,500,000
Senior Notes \| 2013 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	400,000,000	400,000,000
Senior Notes \| 2013 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400,000,000	400,000,000
Senior Notes \| 2013 Senior Notes \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	405,000,000	408,500,000
Senior Notes \| 2012 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	250,000,000	250,000,000
Senior Notes \| 2012 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250,000,000	250,000,000
Senior Notes \| 2012 Senior Notes \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	268,100,000	280,600,000
Term Loans \| 2012 Term Loan \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	217,500,000	287,500,000
Term Loans \| 2012 Term Loan \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	218,000,000	288,900,000
Term Loans \| 2012 Term B-2 Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	662,500,000
Long-term debt, carrying value	660,000,000	0
Revolving Credit Facility \| 2012 ABL Revolver
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	66,100,000	0
Line of credit, fair value disclosure	$ 65,700,000

Stockholders' Equity (Details) (USD $)	12 Months Ended
Stockholders' Equity (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned	1
Dividends declared on common stock	$ 0
Dividends paid on common stock	$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period, shares	59,933	25,464
Restricted stock acquired, average cost per share	$ 34.16	$ 29.23

Earnings Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Numerator
Net income	$ 23,772	$ 21,293	$ 16,463	$ 16,732	$ 16,001	$ 3,130	$ 32,792	$ 20,692	$ 78,260	$ 72,615	$ 65,505
Denominator
Denominator for basic earnings per share- weighted average shares (in shares)	52,356	52,278	52,088	51,956	51,893	51,806	51,463	51,222	52,170	51,641	50,633
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)									500	708	807
Denominator for diluted earnings per share (in shares)	52,821	52,730	52,594	52,533	52,513	52,445	52,219	52,040	52,670	52,349	51,440
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.45	$ 0.41	$ 0.32	$ 0.32	$ 0.31	$ 0.06	$ 0.64	$ 0.40	$ 1.50	$ 1.41	$ 1.29
Diluted net earnings per share (in USD per share)	$ 0.45	$ 0.40	$ 0.31	$ 0.32	$ 0.30	$ 0.06	$ 0.63	$ 0.40	$ 1.49	$ 1.39	$ 1.27

Share-Based Compensation (Narrative) (Details) (USD $)	0 Months Ended				12 Months Ended								0 Months Ended						12 Months Ended	0 Months Ended						12 Months Ended	0 Months Ended		12 Months Ended			0 Months Ended				12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended			1 Months Ended	12 Months Ended
Share-Based Compensation (Narrative) (Details) (USD $)	Aug. 14, 2014	May 12, 2014	Aug. 06, 2012	May 09, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015 Restricted Shares	Mar. 31, 2014 Restricted Shares	Mar. 31, 2013 Restricted Shares	Mar. 31, 2015 Restricted Shares Minimum	Mar. 31, 2015 Restricted Shares Maximum	Aug. 14, 2014 Restricted Stock Units (RSUs) Employee	Aug. 05, 2014 Restricted Stock Units (RSUs) Employee	May 12, 2014 Restricted Stock Units (RSUs) Employee	Nov. 05, 2013 Restricted Stock Units (RSUs) Employee	May 14, 2013 Restricted Stock Units (RSUs) Employee	May 09, 2012 Restricted Stock Units (RSUs) Employee	Mar. 31, 2015 Restricted Stock Units (RSUs) Employee	May 12, 2014 Restricted Stock Units (RSUs) Employee Tranche 1	May 14, 2013 Restricted Stock Units (RSUs) Employee Tranche 1	May 12, 2014 Restricted Stock Units (RSUs) Employee Tranche 2	May 14, 2013 Restricted Stock Units (RSUs) Employee Tranche 2	Jul. 29, 2013 Restricted Stock Units (RSUs) Director	Jun. 29, 2012 Restricted Stock Units (RSUs) Director	Mar. 31, 2015 Restricted Stock Units (RSUs) Director	Aug. 06, 2012 Restricted Stock Units (RSUs) CEO	Aug. 06, 2012 Stock Options	Mar. 31, 2015 Stock Options	Mar. 31, 2014 Stock Options	Mar. 31, 2013 Stock Options	Aug. 06, 2012 Stock Options Common Stock	Aug. 14, 2014 Stock Options Employee	May 12, 2014 Stock Options Employee	May 14, 2013 Stock Options Employee	Mar. 31, 2015 Stock Options Minimum	Aug. 06, 2012 Stock Options Maximum	Mar. 31, 2015 Stock Options Maximum	Aug. 05, 2014 2005 Long-term Equity Incentive Plan	Aug. 04, 2014 2005 Long-term Equity Incentive Plan	May 31, 2014 2005 Long-term Equity Incentive Plan	Jun. 30, 2014 2005 Long-term Equity Incentive Plan	Mar. 31, 2015 2005 Long-term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant																																											5,000,000.0
Number of additional shares authorized under plan																																							1,800,000			1,800,000.0
Maximum number of shares awarded, per employee, annual																																							2,500,000	1,000,000	1,000,000	2,500,000.0
Increase to plan term																																										10 years	10 years
Share-based compensation costs charged against income					$ 6,918,000	$ 5,146,000	$ 3,772,000
Tax benefit recognized from share-based compensation expense					1,900,000	1,500,000	1,200,000
Restricted Shares
Award vesting period											3 years	5 years						3 years	3 years	3 years	3 years	3 years	3 years			1 year		3 years					3 years	3 years	3 years	3 years		5 years
Award settlement period																										6 months
Restricted common stock units granted in period, shares								106,900	126,600	128,900			2,489	7,796	96,638	6,000	113,637	111,152		75,638	55,637	21,000	58,000	7,004	12,652		5,109
Percentage of options vesting annually		33.30%	33.30%															33.30%				33.30%	33.30%										33.30%		33.30%
Granted, weighted-average grant-date fair value (in USD per share)								$ 33.33	$ 30.19	$ 13.59																			$ 15.95	$ 13.94	$ 6.03
Options
Award exercisability period, from date of grant (not greater than)																																	10 years	10 years	10 years		10 years	10 years
Options granted, shares	10,485	307,490		422,962	317,900	227,700	444,900
Options granted, weighted-average exercise price (in USD per share)				$ 13.24	$ 33.54	$ 29.94	$ 13.36
Common shares to be issued upon exercise																																21,978
Options granted, weighted-average grant-date fair value (in USD per share)			$ 15.66																														$ 34.79	$ 33.50	$ 29.94
Options granted in period																																			227,672
Options exercised, intrinsic value					9,300,000
Share-based compensation expense, not yet recognized					4,900,000
Share-based compensation expense, not yet recognized, period for recognition					10 months 24 days
Fair value of awards vested during period					4,700,000	3,400,000	2,500,000
Proceeds from exercise of stock awards					3,954,000	5,907,000	6,029,000
Income tax benefit realized from exercise of stock awards					$ 2,200,000	$ 1,700,000	$ 11,300,000
Number of shares available for issuance under plan																																											3,000,000

Share-Based Compensation (Restricted Shares Activity) (Details) (Restricted Shares, USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Restricted Shares
Shares
Outstanding, beginning of period	437,500	421,300	363,400
Granted	106,900	126,600	128,900
Vested and issued	(154,400)	(104,800)	(58,700)
Forfeited	(27,700)	(5,600)	(12,300)
Outstanding, end of period	362,300	437,500	421,300
Vested, end of period	76,600	69,600	70,400
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 16.76	$ 11.01	$ 9.92
Granted, weighted-average grant-date fair value (in USD per share)	$ 33.33	$ 30.19	$ 13.59
Vested, weighted-average grant-date fair value (in USD per share)	$ 13.37	$ 9.98	$ 9.99
Forfeited, weighted-average grant-date fair value (in USD per share)	$ 21.45	$ 15.11	$ 10.69
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$ 22.74	$ 16.76	$ 11.01
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 11.62	$ 9.34	$ 8.52

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	47.30%	48.00%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	2.20%	1.30%

Share-Based Compensation (Stock Option Activity) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended			12 Months Ended
	Aug. 14, 2014	May 12, 2014	May 09, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Shares
Outstanding, beginning of period				994,900	1,386,400	1,745,400
Granted	10,485	307,490	422,962	317,900	227,700	444,900
Exercised				(386,300)	(605,000)	(786,500)
Forfeited or expired				(55,300)	(14,200)	(17,400)
Outstanding, end of period				871,200	994,900	1,386,400
Exercisable, end of period				312,300
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)				$ 15.24	$ 10.43	$ 8.44
Granted, weighted-average exercise price (in USD per share)			$ 13.24	$ 33.54	$ 29.94	$ 13.36
Exercised, weighted-average exercise price (in USD per share)				$ 10.24	$ 9.76	$ 7.67
Forfeited or expired, weighted-average exercise price (in USD per share)				$ 26.77	$ 14.56	$ 11.21
Outstanding, end of period, weighted-average exercise price (in USD per share)				$ 23.40	$ 15.24	$ 10.43
Exercisable, end of period, weighted-average exercise price (in USD per share)				$ 15.15
Options
Outstanding, end of period, weighted-average remaining contractual term				7 years 8 months 12 days
Exercisable, end of period, weighted-average remaining contractual term				6 years 4 months 24 days
Outstanding, end of period, aggregate intrinsic value				$ 16,978
Exercisable, end of period, aggregate intrinsic value				$ 8,664

Income Taxes (Narrative) (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Ownership percentage	100.00%
Net operating loss carryforwards	$ 65,000,000
Net operating loss carryforwards, tax affected	23,800,000	327,000
Operating loss carryforwards, limitation on use, annual amount	33,000,000
Earnings U.S income taxes not provided by	14,200,000
Uncertain tax liability	$ 1,300,000

Income Taxes (Income Before Continuing Operations) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Income from Continuing Operations before Income Taxes:
United States									$ 122,588	$ 98,786	$ 105,727
Foreign									4,870	2,962	307
Income before income taxes	$ 37,449	$ 33,534	$ 28,325	$ 28,150	$ 26,703	$ 4,186	$ 37,323	$ 33,536	$ 127,458	$ 101,748	$ 106,034

Income Taxes (Components of Provision for Income Taxes) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Current
Federal									$ 13,066	$ 7,801	$ 12,520
State									760	625	1,972
Foreign									3,228	1,675	532
Deferred
Federal									31,012	27,045	23,845
State									1,162	(7,879)	1,660
Foreign									(30)	(134)	0
Total provision for income taxes	$ 13,677	$ 12,241	$ 11,862	$ 11,418	$ 10,702	$ 1,056	$ 4,531	$ 12,844	$ 49,198	$ 29,133	$ 40,529

Income Taxes (Components of Deferred Tax Balances) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 4,106	$ 4,082
Inventory capitalization	1,550	1,301
Inventory reserves	1,495	362
Net operating loss carryforwards	23,800	327
State income taxes	7,557	3,728
Accrued liabilities	619	642
Stock compensation	3,517	2,358
Other	834	702
Total deferred tax assets	43,478	13,502
Deferred Tax Liabilities
Property and equipment	(1,143)	(1,467)
Intangible assets	(385,807)	(218,696)
Total deferred tax liabilities	(386,950)	(220,163)
Net deferred tax liability	$ (343,472)	$ (206,661)

Income Taxes (Reconciliation of Effective Tax Rate) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ 44,610	$ 35,612	$ 37,112
Income tax provision at statutory rate, percentage	35.00%	35.00%	35.00%
Foreign tax (benefit) provision	(2,019)	(918)	0
Foreign tax (benefit) provision, percentage	(1.60%)	(0.90%)	0.00%
State income taxes, net of federal income tax benefit	2,865	2,004	3,413
State income taxes, net of federal income tax benefit, percentage	2.30%	2.00%	3.20%
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	0	(8,892)	(1,741)
Decrease in net deferred tax liability resulting from a change in the effective state tax rate, percentage	0.00%	(8.70%)	(1.60%)
Goodwill impairment	206	0	0
Goodwill impairment, percentage	0.20%	0.00%	0.00%
Transaction costs	2,936	0	0
Transaction costs, percentage	2.30%	0.00%	0.00%
Nondeductible compensation	566	1,011	1,684
Nondeductible compensation, percentage	0.40%	1.00%	1.60%
Other	34	316	61
Other, percentage	0.00%	0.30%	0.00%
Total provision for income taxes	$ 49,198	$ 29,133	$ 40,529
Total provision for income taxes, percentage	38.60%	28.70%	38.20%

Income Taxes (Uncertain Tax Liability Activity) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 1,236	$ 1,016	$ 292
Additions based on tax positions related to the current year	2,229	360	831
Reductions based on lapse of statute of limitations	(45)	(140)	(107)
Balance – end of year	$ 3,420	$ 1,236	$ 1,016

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	12 Months Ended				3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015 Office Facilities	Jun. 30, 2014 Office Facilities New York sqft	Mar. 31, 2015 Equipment
Operating Leased Assets [Line Items]
Office lease, increase in leased area					15,470
2016	$ 1,923,000			$ 1,612,000		$ 311,000
2017	1,849,000			1,772,000		77,000
2018	1,856,000			1,856,000		0
2019	1,864,000			1,864,000		0
2020	2,465,000			2,465,000		0
Total future minimum payments due	9,957,000	4,621,000		9,569,000		388,000
Less: Sublease rentals	(1,401,000)	0
Minimum lease payments, net of sublease rentals	8,556,000	4,621,000
Operating leases, rent expense	$ 1,600,000	$ 1,500,000	$ 1,200,000

Commitments and Contingencies (Long-term Supply Agreement) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015
Long-term Purchase Commitment [Line Items]
2016	$ 1,074
2017	1,044
2018	1,013
2019	982
2020	560
Thereafter	0
Total purchase commitment	$ 4,673
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Mar. 31, 2015 brand	Mar. 31, 2014	Mar. 31, 2013
Concentration Risk [Line Items]
Number of third-party manufacturers	95
Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	38.20%	38.30%	40.50%
Number of highest selling brands comprising group against which concentration risk is measured	5
Sales \| Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers exceeding concentration risk benchmark		1	1
Sales \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	18.10%	19.50%	15.90%
Number of customers exceeding concentration risk benchmark	1
Sales \| Customer Concentration Risk \| Next largest customer
Concentration Risk [Line Items]
Concentration risk, percentage	8.40%
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	82.90%	82.40%
Number of third-party manufacturers with long-term contracts	44	24
Accounts Receivable \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	23.00%
Accounts Receivable \| Customer Concentration Risk \| Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage	10.50%

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information, Profit (Loss):
Gross segment revenues									$ 713,457	$ 595,639	$ 616,915
Elimination of intersegment revenues									(3,387)	(3,185)	0
Third-party segment revenues									710,070	592,454	616,915
Other revenues									4,553	4,927	3,203
Total revenues	190,046	197,606	181,269	145,702	143,053	144,871	166,945	142,512	714,623	597,381	620,118
Cost of sales	79,976	85,861	78,727	63,836	64,216	64,403	73,723	59,488	308,400	261,830	276,381
Gross profit	110,070	111,745	102,542	81,866	78,837	80,468	93,222	83,024	406,223	335,551	343,737
Advertising and promotion	25,367	30,144	25,044	19,096	17,511	24,229	24,547	18,681	99,651	84,968	87,151
Contribution margin									306,572	250,583	256,586
Other operating expenses									99,013	61,967	64,702
Operating income	61,245	56,993	46,518	42,803	44,955	40,458	53,762	49,441	207,559	188,616	191,884
Other expense									80,101	86,868	85,850
Income before income taxes	37,449	33,534	28,325	28,150	26,703	4,186	37,323	33,536	127,458	101,748	106,034
Provision for income taxes	13,677	12,241	11,862	11,418	10,702	1,056	4,531	12,844	49,198	29,133	40,529
Net income	23,772	21,293	16,463	16,732	16,001	3,130	32,792	20,692	78,260	72,615	65,505
Geographic Concentration Risk \| Sales \| United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage									85.20%	86.90%	89.90%
Geographic Concentration Risk \| Sales \| Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage									5.90%	7.70%	7.40%
Geographic Concentration Risk \| Sales \| Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage									6.90%
Geographic Concentration Risk \| Goodwill and Intangible Assets \| United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage									95.60%
Geographic Concentration Risk \| Goodwill and Intangible Assets \| Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage									4.40%
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues									61,116	29,872	14,493
Elimination of intersegment revenues									0	0	0
Third-party segment revenues									61,116	29,872	14,493
Other revenues									64	42	45
Total revenues									61,180	29,914	14,538
Cost of sales									22,820	12,646	6,265
Gross profit									38,360	17,268	8,273
Advertising and promotion									10,922	5,264	1,643
Contribution margin									27,438	12,004	6,630
Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues									86,085	83,629	83,376
Elimination of intersegment revenues									0	0	0
Third-party segment revenues									86,085	83,629	83,376
Other revenues									3,852	4,136	2,519
Total revenues									89,937	87,765	85,895
Cost of sales									68,799	64,388	64,727
Gross profit									21,138	23,377	21,168
Advertising and promotion									1,832	2,621	5,457
Contribution margin									19,306	20,756	15,711
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues									566,256	482,138	519,046
Elimination of intersegment revenues									(3,387)	(3,185)	0
Third-party segment revenues									562,869	478,953	519,046
Other revenues									637	749	639
Total revenues									563,506	479,702	519,685
Cost of sales									216,781	184,796	205,389
Gross profit									346,725	294,906	314,296
Advertising and promotion									86,897	77,083	80,051
Contribution margin									$ 259,828	$ 217,823	$ 234,245

Business Segments (Revenue by Product) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Revenue from External Customer [Line Items]
Total revenues	$ 190,046	$ 197,606	$ 181,269	$ 145,702	$ 143,053	$ 144,871	$ 166,945	$ 142,512	$ 714,623	$ 597,381	$ 620,118
Analgesics
Revenue from External Customer [Line Items]
Total revenues									114,551	109,984	107,517
Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									121,766	113,425	125,791
Women's Health
Revenue from External Customer [Line Items]
Total revenues									73,767	3,795	2,544
Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									96,968	82,307	97,618
Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									97,925	85,491	86,076
Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									67,095	58,091	56,513
Oral Care
Revenue from External Customer [Line Items]
Total revenues									46,399	48,313	49,421
Other OTC
Revenue from External Customer [Line Items]
Total revenues									6,215	8,210	8,743
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									89,937	87,765	85,895
International OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									61,180	29,914	14,538
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									2,597	1,883	245
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									18,080	13,365	4,277
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									2,261	1,835	0
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									19,372	838	82
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									16,076	9,923	9,116
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									2,289	1,655	399
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									483	413	419
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									22	2	0
International OTC Healthcare \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									0	0	0
North American OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									563,506	479,702	519,685
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									111,954	108,101	107,272
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									103,686	100,060	121,514
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									71,506	1,960	2,544
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									77,596	81,469	97,536
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									81,849	75,568	76,960
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									64,806	56,436	56,114
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									45,916	47,900	49,002
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									6,193	8,208	8,743
North American OTC Healthcare \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									89,937	87,765	85,895
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									$ 89,937	$ 87,765	$ 85,895

Business Segments (Assets by Segment) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 290,651	$ 190,911	$ 167,546	$ 173,702
Indefinite-lived intangibles	1,873,404
Finite-lived intangibles	261,296
Intangible assets, net (excluding goodwill)	2,134,700	1,394,817	1,373,240
Intangible assets, net (including goodwill)	2,425,351
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	263,411	160,157	160,157	166,313
Indefinite-lived intangibles	1,676,991
Finite-lived intangibles	235,642
Intangible assets, net (excluding goodwill)	1,912,633	1,217,139	1,225,509
Intangible assets, net (including goodwill)	2,176,044
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	20,440	23,365	0	0
Indefinite-lived intangibles	86,141
Finite-lived intangibles	1,231
Intangible assets, net (excluding goodwill)	87,372	31,691	0
Intangible assets, net (including goodwill)	107,812
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	7,389	7,389	7,389
Indefinite-lived intangibles	110,272
Finite-lived intangibles	24,423
Intangible assets, net (excluding goodwill)	134,695	145,987	147,731
Intangible assets, net (including goodwill)	$ 141,495

Unaudited Quarterly Financial Information (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 190,046	$ 197,606	$ 181,269	$ 145,702	$ 143,053	$ 144,871	$ 166,945	$ 142,512	$ 714,623	$ 597,381	$ 620,118
Cost of sales (exclusive of depreciation shown below)	79,976	85,861	78,727	63,836	64,216	64,403	73,723	59,488	308,400	261,830	276,381
Gross profit	110,070	111,745	102,542	81,866	78,837	80,468	93,222	83,024	406,223	335,551	343,737
Operating Expenses
Advertising and promotion	25,367	30,144	25,044	19,096	17,511	24,229	24,547	18,681	99,651	84,968	87,151
General and administrative	17,685	19,454	27,128	17,006	13,091	12,137	11,619	11,634	81,273	48,481	51,467
Depreciation and amortization	5,773	5,154	3,852	2,961	3,280	3,644	3,294	3,268	17,740	13,486	13,235
Total operating expenses	48,825	54,752	56,024	39,063	33,882	40,010	39,460	33,583	198,664	146,935	151,853
Operating income	61,245	56,993	46,518	42,803	44,955	40,458	53,762	49,441	207,559	188,616	191,884
Net interest expense	23,796	24,592	18,193	14,653	14,978	21,260	16,439	15,905
Gain on sale of asset	0	1,133	0	0
Loss on extinguishment of debt					3,274	15,012	0	0	0	18,286	1,443
Income before income taxes	37,449	33,534	28,325	28,150	26,703	4,186	37,323	33,536	127,458	101,748	106,034
Provision for income taxes	13,677	12,241	11,862	11,418	10,702	1,056	4,531	12,844	49,198	29,133	40,529
Net income	23,772	21,293	16,463	16,732	16,001	3,130	32,792	20,692	78,260	72,615	65,505
Earnings per share:
Basic (in USD per share)	$ 0.45	$ 0.41	$ 0.32	$ 0.32	$ 0.31	$ 0.06	$ 0.64	$ 0.40	$ 1.50	$ 1.41	$ 1.29
Diluted (in USD per share)	$ 0.45	$ 0.40	$ 0.31	$ 0.32	$ 0.30	$ 0.06	$ 0.63	$ 0.40	$ 1.49	$ 1.39	$ 1.27
Weighted average shares outstanding:
Basic (in shares)	52,356	52,278	52,088	51,956	51,893	51,806	51,463	51,222	52,170	51,641	50,633
Diluted (in shares)	52,821	52,730	52,594	52,533	52,513	52,445	52,219	52,040	52,670	52,349	51,440
Comprehensive income, net of tax:
Currency translation adjustments	(7,268)	(8,779)	(10,830)	2,726	2,414	(2,694)	1,122	1	(24,151)	843	(91)
Total other comprehensive income (loss)	(7,268)	(8,779)	(10,830)	2,726	2,414	(2,694)	1,122	1	(24,151)	843	(91)
Comprehensive income	$ 16,504	$ 12,514	$ 5,633	$ 19,458	$ 18,415	$ 436	$ 33,914	$ 20,693	$ 54,109	$ 73,458	$ 65,414

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Revenues
Net sales									$ 710,070	$ 592,454	$ 616,915
Other revenues									4,553	4,927	3,203
Total revenues	190,046	197,606	181,269	145,702	143,053	144,871	166,945	142,512	714,623	597,381	620,118
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	79,976	85,861	78,727	63,836	64,216	64,403	73,723	59,488	308,400	261,830	276,381
Gross profit	110,070	111,745	102,542	81,866	78,837	80,468	93,222	83,024	406,223	335,551	343,737
Operating Expenses
Advertising and promotion	25,367	30,144	25,044	19,096	17,511	24,229	24,547	18,681	99,651	84,968	87,151
General and administrative	17,685	19,454	27,128	17,006	13,091	12,137	11,619	11,634	81,273	48,481	51,467
Depreciation and amortization	5,773	5,154	3,852	2,961	3,280	3,644	3,294	3,268	17,740	13,486	13,235
Total operating expenses	48,825	54,752	56,024	39,063	33,882	40,010	39,460	33,583	198,664	146,935	151,853
Operating income	61,245	56,993	46,518	42,803	44,955	40,458	53,762	49,441	207,559	188,616	191,884
Other (income) expense
Interest income									(92)	(60)	(13)
Interest expense									81,326	68,642	84,420
Gain on sale of asset									1,133	0	0
Loss on extinguishment of debt					3,274	15,012	0	0	0	18,286	1,443
Equity in income of subsidiaries									0	0	0
Total other expense									80,101	86,868	85,850
Income before income taxes	37,449	33,534	28,325	28,150	26,703	4,186	37,323	33,536	127,458	101,748	106,034
Provision for income taxes	13,677	12,241	11,862	11,418	10,702	1,056	4,531	12,844	49,198	29,133	40,529
Net income (loss)	23,772	21,293	16,463	16,732	16,001	3,130	32,792	20,692	78,260	72,615	65,505
Comprehensive income, net of tax:
Currency translation adjustments									(24,151)	843	(91)
Total other comprehensive income (loss)	(7,268)	(8,779)	(10,830)	2,726	2,414	(2,694)	1,122	1	(24,151)	843	(91)
Comprehensive income	16,504	12,514	5,633	19,458	18,415	436	33,914	20,693	54,109	73,458	65,414
Prestige Brands Holdings, Inc.
Revenues
Net sales									0	0	0
Other revenues									0	0	0
Total revenues									0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									0	0	0
Gross profit									0	0	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									4,571	3,140	5,127
Depreciation and amortization									3,381	2,994	1,346
Total operating expenses									7,952	6,134	6,473
Operating income									(7,952)	(6,134)	(6,473)
Other (income) expense
Interest income									(48,543)	(48,730)	(30,561)
Interest expense									34,198	34,436	34,671
Gain on sale of asset									0
Loss on extinguishment of debt										0	0
Equity in income of subsidiaries									(76,383)	(66,739)	(72,295)
Total other expense									(90,728)	(81,033)	(68,185)
Income before income taxes									82,776	74,899	61,712
Provision for income taxes									4,516	2,284	(3,793)
Net income (loss)									78,260	72,615	65,505
Comprehensive income, net of tax:
Currency translation adjustments									(24,151)	843	(91)
Total other comprehensive income (loss)									(24,151)	843	(91)
Comprehensive income									54,109	73,458	65,414
Prestige Brands, Inc., the issuer
Revenues
Net sales									106,439	97,509	102,203
Other revenues									385	295	278
Total revenues									106,824	97,804	102,481
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									39,637	37,272	39,333
Gross profit									67,187	60,532	63,148
Operating Expenses
Advertising and promotion									8,828	10,223	12,102
General and administrative									9,090	8,026	6,917
Depreciation and amortization									592	577	569
Total operating expenses									18,510	18,826	19,588
Operating income									48,677	41,706	43,560
Other (income) expense
Interest income									(73,755)	(57,446)	(57,496)
Interest expense									81,326	68,642	84,420
Gain on sale of asset									0
Loss on extinguishment of debt										18,286	1,443
Equity in income of subsidiaries									(51,573)	(53,836)	(65,784)
Total other expense									(44,002)	(24,354)	(37,417)
Income before income taxes									92,679	66,060	80,977
Provision for income taxes									14,798	3,500	5,807
Net income (loss)									77,881	62,560	75,170
Comprehensive income, net of tax:
Currency translation adjustments									(24,151)	843	0
Total other comprehensive income (loss)									(24,151)	843	0
Comprehensive income									53,730	63,403	75,170
Combined Subsidiary Guarantors
Revenues
Net sales									555,388	474,338	510,041
Other revenues									4,452	4,886	3,158
Total revenues									559,840	479,224	513,199
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									254,670	218,692	236,795
Gross profit									305,170	260,532	276,404
Operating Expenses
Advertising and promotion									79,944	69,583	73,623
General and administrative									55,209	34,469	38,713
Depreciation and amortization									12,752	9,715	11,261
Total operating expenses									147,905	113,767	123,597
Operating income									157,265	146,765	152,807
Other (income) expense
Interest income									(5,373)	(2,327)	0
Interest expense									88,464	72,064	53,374
Gain on sale of asset									1,133
Loss on extinguishment of debt										0	0
Equity in income of subsidiaries									(2,013)	(4,052)	(1,482)
Total other expense									79,945	65,685	51,892
Income before income taxes									77,320	81,080	100,915
Provision for income taxes									27,111	22,055	38,006
Net income (loss)									50,209	59,025	62,909
Comprehensive income, net of tax:
Currency translation adjustments									(24,151)	843	0
Total other comprehensive income (loss)									(24,151)	843	0
Comprehensive income									26,058	59,868	62,909
Combined Non-guarantor Subsidiaries
Revenues
Net sales									51,630	23,286	4,671
Other revenues									1,497	1,639	1,517
Total revenues									53,127	24,925	6,188
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									19,127	9,428	2,003
Gross profit									34,000	15,497	4,185
Operating Expenses
Advertising and promotion									10,879	5,162	1,426
General and administrative									12,403	2,846	710
Depreciation and amortization									1,015	200	59
Total operating expenses									24,297	8,208	2,195
Operating income									9,703	7,289	1,990
Other (income) expense
Interest income									(456)	(382)	(1)
Interest expense									5,373	2,325	0
Gain on sale of asset									0
Loss on extinguishment of debt										0	0
Equity in income of subsidiaries									0	0	0
Total other expense									4,917	1,943	(1)
Income before income taxes									4,786	5,346	1,991
Provision for income taxes									2,773	1,294	509
Net income (loss)									2,013	4,052	1,482
Comprehensive income, net of tax:
Currency translation adjustments									(24,151)	843	(91)
Total other comprehensive income (loss)									(24,151)	843	(91)
Comprehensive income									(22,138)	4,895	1,391
Eliminations
Revenues
Net sales									(3,387)	(2,679)	0
Other revenues									(1,781)	(1,893)	(1,750)
Total revenues									(5,168)	(4,572)	(1,750)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									(5,034)	(3,562)	(1,750)
Gross profit									(134)	(1,010)	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									0	0	0
Operating income									(134)	(1,010)	0
Other (income) expense
Interest income									128,035	108,825	88,045
Interest expense									(128,035)	(108,825)	(88,045)
Gain on sale of asset									0
Loss on extinguishment of debt										0	0
Equity in income of subsidiaries									129,969	124,627	139,561
Total other expense									129,969	124,627	139,561
Income before income taxes									(130,103)	(125,637)	(139,561)
Provision for income taxes									0	0	0
Net income (loss)									(130,103)	(125,637)	(139,561)
Comprehensive income, net of tax:
Currency translation adjustments									72,453	(2,529)	91
Total other comprehensive income (loss)									72,453	(2,529)	91
Comprehensive income									$ (57,650)	$ (128,166)	$ (139,470)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$ 21,318	$ 28,331	$ 15,670	$ 19,015
Accounts receivable, net	87,858	65,050
Inventories	74,000	65,586
Deferred income tax assets	8,097	6,544
Prepaid expenses and other current assets	10,434	11,674
Total current assets	201,707	177,185
Property and equipment, net	13,744	9,597
Goodwill	290,651	190,911	167,546	173,702
Intangible assets, net	2,134,700	1,394,817	1,373,240
Other long-term assets	28,603	23,153
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,669,405	1,795,663
Current liabilities
Accounts payable	46,115	48,286
Accrued interest payable	11,974	9,626
Other accrued liabilities	40,948	26,446
Total current liabilities	99,037	84,358
Long-term debt
Principal amount	1,593,600	937,500
Less unamortized discount	(4,889)	(3,086)
Long-term debt, net of unamortized discount	1,588,711	934,414
Deferred income tax liabilities	351,569	213,204
Other long-term liabilities	2,464	327
Intercompany payables	0	0
Total Liabilities	2,041,781	1,232,303
Stockholders’ Equity
Common stock	525	520
Additional paid-in capital	426,584	414,387
Treasury stock, at cost	(3,478)	(1,431)
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings (accumulated deficit)	227,405	149,145
Total Stockholders’ Equity	627,624	563,360	477,943	402,728
Total Liabilities and Stockholders’ Equity	2,669,405	1,795,663
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	11,387	24,644	14,720	18,221
Accounts receivable, net	0	473
Inventories	0	0
Deferred income tax assets	452	260
Prepaid expenses and other current assets	5,731	8,004
Total current assets	17,570	33,381
Property and equipment, net	10,726	8,966
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,210,017	655,146
Investment in subsidiary	1,545,575	1,497,357
Total Assets	2,783,888	2,194,850
Current liabilities
Accounts payable	1,959	4,416
Accrued interest payable	0	0
Other accrued liabilities	10,378	7,728
Total current liabilities	12,337	12,144
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,143,927	1,619,346
Total Liabilities	2,156,264	1,631,490
Stockholders’ Equity
Common stock	525	520
Additional paid-in capital	426,584	414,387
Treasury stock, at cost	(3,478)	(1,431)
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings (accumulated deficit)	227,405	149,145
Total Stockholders’ Equity	627,624	563,360
Total Liabilities and Stockholders’ Equity	2,783,888	2,194,850
Prestige Brands, Inc., the issuer
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,539	14,245
Inventories	8,667	14,357
Deferred income tax assets	674	925
Prepaid expenses and other current assets	141	113
Total current assets	24,021	29,640
Property and equipment, net	175	112
Goodwill	66,007	66,007
Intangible assets, net	192,325	192,861
Other long-term assets	28,603	23,153
Intercompany receivables	2,607,054	1,824,482
Investment in subsidiary	1,228,535	749,947
Total Assets	4,146,720	2,886,202
Current liabilities
Accounts payable	6,829	7,658
Accrued interest payable	11,974	9,626
Other accrued liabilities	1,153	2,117
Total current liabilities	19,956	19,401
Long-term debt
Principal amount	1,593,600	937,500
Less unamortized discount	(4,889)	(3,086)
Long-term debt, net of unamortized discount	1,588,711	934,414
Deferred income tax liabilities	59,038	56,827
Other long-term liabilities	0	0
Intercompany payables	1,001,219	451,497
Total Liabilities	2,668,924	1,462,139
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	1,280,948	1,280,945
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings (accumulated deficit)	220,260	142,379
Total Stockholders’ Equity	1,477,796	1,424,063
Total Liabilities and Stockholders’ Equity	4,146,720	2,886,202
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	66,523	45,885
Inventories	60,297	46,309
Deferred income tax assets	6,497	4,914
Prepaid expenses and other current assets	3,804	2,898
Total current assets	137,121	100,006
Property and equipment, net	2,207	226
Goodwill	204,205	101,540
Intangible assets, net	1,854,798	1,169,943
Other long-term assets	0	0
Intercompany receivables	668,169	656,759
Investment in subsidiary	65,564	34,562
Total Assets	2,932,064	2,063,036
Current liabilities
Accounts payable	32,898	33,553
Accrued interest payable	0	0
Other accrued liabilities	25,795	13,443
Total current liabilities	58,693	46,996
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	292,504	156,327
Other long-term liabilities	2,293	0
Intercompany payables	1,279,833	1,037,105
Total Liabilities	1,633,323	1,240,428
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	1,131,578	681,503
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings (accumulated deficit)	190,575	140,366
Total Stockholders’ Equity	1,298,741	822,608
Total Liabilities and Stockholders’ Equity	2,932,064	2,063,036
Combined Non-guarantor Subsidiaries
Current assets
Cash and cash equivalents	9,931	3,687	950	794
Accounts receivable, net	6,796	4,447
Inventories	6,182	5,930
Deferred income tax assets	474	445
Prepaid expenses and other current assets	758	659
Total current assets	24,141	15,168
Property and equipment, net	636	293
Goodwill	20,439	23,364
Intangible assets, net	87,577	32,013
Other long-term assets	0	0
Intercompany receivables	8,764	13,595
Investment in subsidiary	0	0
Total Assets	141,557	84,433
Current liabilities
Accounts payable	4,429	2,659
Accrued interest payable	0	0
Other accrued liabilities	3,622	3,158
Total current liabilities	8,051	5,817
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	27	50
Other long-term liabilities	171	327
Intercompany payables	69,025	42,034
Total Liabilities	77,274	48,228
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	74,031	23,815
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,412)	739
Retained earnings (accumulated deficit)	13,664	11,651
Total Stockholders’ Equity	64,283	36,205
Total Liabilities and Stockholders’ Equity	141,557	84,433
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	(1,146)	(1,010)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(1,146)	(1,010)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(4,494,004)	(3,149,982)
Investment in subsidiary	(2,839,674)	(2,281,866)
Total Assets	(7,334,824)	(5,432,858)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(4,494,004)	(3,149,982)
Total Liabilities	(4,494,004)	(3,149,982)
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	(2,486,557)	(1,986,263)
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	70,236	(2,217)
Retained earnings (accumulated deficit)	(424,499)	(294,396)
Total Stockholders’ Equity	(2,840,820)	(2,282,876)
Total Liabilities and Stockholders’ Equity	$ (7,334,824)	$ (5,432,858)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Operating Activities
Net income (loss)	$ 78,260	$ 72,615	$ 65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	17,740	13,486	13,235
Gain on sale of asset	(1,133)	0	0
Deferred income taxes	28,922	19,012	25,505
Long term income taxes payable	2,294	0	0
Amortization of deferred financing costs	6,735	7,102	9,832
Stock-based compensation costs	6,918	5,146	3,772
Loss on extinguishment of debt	0	18,286	1,443
Premium payment on 2010 Senior Notes	0	(15,527)	0
Amortization of debt discount	2,086	3,410	4,632
Lease termination costs	785	0	975
Loss (gain) on sale or disposal of equipment	321	(3)	103
Equity in income of subsidiaries	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	1,608	9,735	(12,882)
Inventories	15,360	(2,850)	(9,342)
Prepaid expenses and other current assets	4,664	(2,130)	3,096
Accounts payable	(17,637)	(4,641)	24,677
Accrued liabilities	9,332	(12,059)	7,054
Net cash provided by operating activities	156,255	111,582	137,605
Investing Activities
Purchases of property and equipment	(6,101)	(2,764)	(10,268)
Proceeds from sale of property and equipment	0	3	15
Proceeds from sale of asset	0	0	21,700
Acquisition of brands from GSK purchase price adjustments	0	0	226
Proceeds from sale of asset	10,000	0	0
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666)	0	0
Acquisition of the Hydralyte brand	(77,991)	0	0
Intercompany activity, net	0	0	0
Net cash (used in) provided by investing activities	(805,258)	(57,976)	11,221
Financing Activities
Proceeds from issuance of 2013 Senior Notes	0	400,000	0
Term loan borrowings	720,000	0	0
Term loan repayments	(130,000)	(157,500)	(190,000)
Repayment of 2010 Senior Notes	0	(250,000)	0
Borrowings under revolving credit agreement	124,600	50,000	48,000
Proceeds from restricted stock exercises	57	0	0
Repayments of Lines of Credit	(58,500)	(83,000)	(15,000)
Payment of deferred financing costs	(16,072)	(7,466)	(1,146)
Proceeds from issuance of 2012 Term Loan			48,000
Proceeds from exercise of stock options	3,954	5,907	6,029
Excess tax benefits from share-based awards	1,330	1,650	0
Fair value of shares surrendered as payment of tax withholding	(2,104)	(744)	0
Intercompany activity, net	0	0	0
Net cash provided by (used in) financing activities	643,265	(41,153)	(152,117)
Effects of exchange rate changes on cash and cash equivalents	(1,275)	208	(54)
Increase (decrease) in cash and cash equivalents	(7,013)	12,661	(3,345)
Cash and cash equivalents - beginning of year	28,331	15,670	19,015
Cash and cash equivalents - end of year	21,318	28,331	15,670
Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	18,500	0	0
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	78,260	72,615	65,505
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	3,381	2,994	1,346
Gain on sale of asset	0
Deferred income taxes	(192)	(42)	138
Long term income taxes payable	0
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	6,918	5,146	3,772
Loss on extinguishment of debt		0	0
Premium payment on 2010 Senior Notes		0
Amortization of debt discount	0	0	0
Lease termination costs	0		975
Loss (gain) on sale or disposal of equipment	0	0	82
Equity in income of subsidiaries	(76,383)	(66,739)	(72,295)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	473	(452)	4
Inventories	0	0	0
Prepaid expenses and other current assets	2,273	(3,062)	3,160
Accounts payable	(2,457)	1,815	(1,930)
Accrued liabilities	2,650	(4,966)	(39)
Net cash provided by operating activities	14,923	7,309	718
Investing Activities
Purchases of property and equipment	(5,029)	(2,351)	(10,268)
Proceeds from sale of property and equipment		0	0
Proceeds from sale of asset			0
Acquisition of brands from GSK purchase price adjustments			0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Intercompany activity, net	0	0	(226)
Net cash (used in) provided by investing activities	(5,029)	(2,351)	(10,494)
Financing Activities
Proceeds from issuance of 2013 Senior Notes		0
Term loan borrowings	0
Term loan repayments	0	0	0
Repayment of 2010 Senior Notes		0
Borrowings under revolving credit agreement	0	0
Proceeds from restricted stock exercises	57
Repayments of Lines of Credit	0	0	0
Payment of deferred financing costs	0	0	0
Proceeds from issuance of 2012 Term Loan			0
Proceeds from exercise of stock options	3,954	5,907	6,029
Excess tax benefits from share-based awards	1,330	1,650
Fair value of shares surrendered as payment of tax withholding	(2,104)	(744)
Intercompany activity, net	26,388	1,847	(246)
Net cash provided by (used in) financing activities	(23,151)	4,966	6,275
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	(13,257)	9,924	(3,501)
Cash and cash equivalents - beginning of year	24,644	14,720	18,221
Cash and cash equivalents - end of year	11,387	24,644	14,720
Prestige Brands Holdings, Inc. \| Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	0
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)	77,881	62,560	75,170
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	592	577	569
Gain on sale of asset	0
Deferred income taxes	2,462	1,466	4,341
Long term income taxes payable	0
Amortization of deferred financing costs	6,735	7,102	9,832
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt		18,286	1,443
Premium payment on 2010 Senior Notes		(15,527)
Amortization of debt discount	2,086	3,410	4,632
Lease termination costs	0		0
Loss (gain) on sale or disposal of equipment	0	0	0
Equity in income of subsidiaries	(51,573)	(53,836)	(65,784)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(294)	(370)	(373)
Inventories	5,690	(3,193)	(3,066)
Prepaid expenses and other current assets	(28)	(20)	(37)
Accounts payable	(829)	(2,942)	5,784
Accrued liabilities	1,384	(3,835)	2
Net cash provided by operating activities	44,106	13,678	32,513
Investing Activities
Purchases of property and equipment	(119)	(119)	0
Proceeds from sale of property and equipment		0	0
Proceeds from sale of asset			0
Acquisition of brands from GSK purchase price adjustments			0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Intercompany activity, net	(809,157)	(55,215)	0
Net cash (used in) provided by investing activities	(809,276)	(55,334)	0
Financing Activities
Proceeds from issuance of 2013 Senior Notes		400,000
Term loan borrowings	720,000
Term loan repayments	(130,000)	(157,500)	(190,000)
Repayment of 2010 Senior Notes		(250,000)
Borrowings under revolving credit agreement	124,600	50,000
Proceeds from restricted stock exercises	0
Repayments of Lines of Credit	(58,500)	(83,000)	(15,000)
Payment of deferred financing costs	(16,072)	(7,466)	(1,146)
Proceeds from issuance of 2012 Term Loan			48,000
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	(125,142)	(89,622)	(125,633)
Net cash provided by (used in) financing activities	765,170	41,656	(32,513)
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	0	0	0
Prestige Brands, Inc., the issuer \| Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	50,209	59,025	62,909
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	12,752	9,715	11,261
Gain on sale of asset	(1,133)
Deferred income taxes	26,795	17,765	21,036
Long term income taxes payable	2,294
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt		0	0
Premium payment on 2010 Senior Notes		0
Amortization of debt discount	0	0	0
Lease termination costs	785		0
Loss (gain) on sale or disposal of equipment	0	(3)	21
Equity in income of subsidiaries	(2,013)	(4,052)	(1,482)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	5,146	12,460	(12,391)
Inventories	8,981	2,165	(6,360)
Prepaid expenses and other current assets	2,631	711	(135)
Accounts payable	(16,734)	(4,142)	20,687
Accrued liabilities	3,560	(2,664)	7,069
Net cash provided by operating activities	93,273	90,980	102,615
Investing Activities
Purchases of property and equipment	(739)	(108)	0
Proceeds from sale of property and equipment		3	15
Proceeds from sale of asset			21,700
Acquisition of brands from GSK purchase price adjustments			226
Proceeds from sale of asset	10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666)
Acquisition of the Hydralyte brand	0
Intercompany activity, net	731,166	0	226
Net cash (used in) provided by investing activities	9,261	(105)	21,715
Financing Activities
Proceeds from issuance of 2013 Senior Notes		0
Term loan borrowings	0
Term loan repayments	0	0	0
Repayment of 2010 Senior Notes		0
Borrowings under revolving credit agreement	0	0
Proceeds from restricted stock exercises	0
Repayments of Lines of Credit	0	0	0
Payment of deferred financing costs	0	0	0
Proceeds from issuance of 2012 Term Loan			0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	102,534	90,875	124,330
Net cash provided by (used in) financing activities	(102,534)	(90,875)	(124,330)
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	0	0	0
Combined Subsidiary Guarantors \| Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	18,500
Combined Non-guarantor Subsidiaries
Operating Activities
Net income (loss)	2,013	4,052	1,482
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,015	200	59
Gain on sale of asset	0
Deferred income taxes	(143)	(177)	(10)
Long term income taxes payable	0
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt		0	0
Premium payment on 2010 Senior Notes		0
Amortization of debt discount	0	0	0
Lease termination costs	0		0
Loss (gain) on sale or disposal of equipment	321	0	0
Equity in income of subsidiaries	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(3,717)	(1,903)	(122)
Inventories	555	(2,832)	84
Prepaid expenses and other current assets	(212)	241	108
Accounts payable	2,383	628	136
Accrued liabilities	1,738	(594)	22
Net cash provided by operating activities	3,953	(385)	1,759
Investing Activities
Purchases of property and equipment	(214)	(186)	0
Proceeds from sale of property and equipment		0	0
Proceeds from sale of asset			0
Acquisition of brands from GSK purchase price adjustments			0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	(77,991)
Intercompany activity, net	77,991	55,215	0
Net cash (used in) provided by investing activities	(214)	(186)	0
Financing Activities
Proceeds from issuance of 2013 Senior Notes		0
Term loan borrowings	0
Term loan repayments	0	0	0
Repayment of 2010 Senior Notes		0
Borrowings under revolving credit agreement	0	0
Proceeds from restricted stock exercises	0
Repayments of Lines of Credit	0	0	0
Payment of deferred financing costs	0	0	0
Proceeds from issuance of 2012 Term Loan			0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	(3,780)	(3,100)	1,549
Net cash provided by (used in) financing activities	3,780	3,100	(1,549)
Effects of exchange rate changes on cash and cash equivalents	(1,275)	208	(54)
Increase (decrease) in cash and cash equivalents	6,244	2,737	156
Cash and cash equivalents - beginning of year	3,687	950	794
Cash and cash equivalents - end of year	9,931	3,687	950
Combined Non-guarantor Subsidiaries \| Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	0
Eliminations
Operating Activities
Net income (loss)	(130,103)	(125,637)	(139,561)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	0	0	0
Gain on sale of asset	0
Deferred income taxes	0	0	0
Long term income taxes payable	0
Amortization of deferred financing costs	0	0	0
Stock-based compensation costs	0	0	0
Loss on extinguishment of debt		0	0
Premium payment on 2010 Senior Notes		0
Amortization of debt discount	0	0	0
Lease termination costs	0		0
Loss (gain) on sale or disposal of equipment	0	0	0
Equity in income of subsidiaries	129,969	124,627	139,561
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0	0
Inventories	134	1,010	0
Prepaid expenses and other current assets	0	0	0
Accounts payable	0	0	0
Accrued liabilities	0	0	0
Net cash provided by operating activities	0	0	0
Investing Activities
Purchases of property and equipment	0	0	0
Proceeds from sale of property and equipment		0	0
Proceeds from sale of asset			0
Acquisition of brands from GSK purchase price adjustments			0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Intercompany activity, net	0	0	0
Net cash (used in) provided by investing activities	0	0	0
Financing Activities
Proceeds from issuance of 2013 Senior Notes		0
Term loan borrowings	0
Term loan repayments	0	0	0
Repayment of 2010 Senior Notes		0
Borrowings under revolving credit agreement	0	0
Proceeds from restricted stock exercises	0
Repayments of Lines of Credit	0	0	0
Payment of deferred financing costs	0	0	0
Proceeds from issuance of 2012 Term Loan			0
Proceeds from exercise of stock options	0	0	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0	0
Net cash provided by (used in) financing activities	0	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents - beginning of year	0	0	0
Cash and cash equivalents - end of year	0	0	0
Eliminations \| Disposal Group, Cutex
Investing Activities
Proceeds from sale of asset	0
Care Pharma
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired	0	(55,215)	0
Care Pharma \| Prestige Brands Holdings, Inc.
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired		0
Care Pharma \| Prestige Brands, Inc., the issuer
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired		0
Care Pharma \| Combined Subsidiary Guarantors
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired		0
Care Pharma \| Combined Non-guarantor Subsidiaries
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired		(55,215)
Care Pharma \| Eliminations
Investing Activities
Acquisition of Insight Pharmaceuticals, less cash acquired		$ 0

Subsequent Events (Details) (USD $)	0 Months Ended				12 Months Ended			0 Months Ended								0 Months Ended				0 Months Ended
Subsequent Events (Details) (USD $)	Aug. 14, 2014	May 12, 2014	Aug. 06, 2012	May 09, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Aug. 06, 2012 Restricted Stock Units (RSUs) President and Chief Executive Officer	May 11, 2015 Subsequent Event	Apr. 22, 2015 Subsequent Event President and Chief Executive Officer	May 11, 2015 Subsequent Event Leo Burnett Company, Inc. Vice Chairman and Chief Operating Officer	May 11, 2015 Subsequent Event Restricted Stock Units (RSUs)	May 11, 2015 Subsequent Event Restricted Stock Units (RSUs) Tranche 1	May 11, 2015 Subsequent Event Restricted Stock Units (RSUs) Tranche 2	May 08, 2015 Subsequent Event 2012 Term Loan, Amendment No. 3 2012 Term B-3 Loan	May 08, 2015 Subsequent Event 2012 Term Loan, Amendment No. 3 2012 Term B-3 Loan LIBOR	May 08, 2015 Subsequent Event 2012 Term Loan, Amendment No. 3 2012 Term B-3 Loan Base Rate	May 08, 2015 Subsequent Event 2012 Term Loan, Amendment No. 3 2012 Term B-1 Loan	May 08, 2015 Subsequent Event 2012 Term Loan, Amendment No. 3 2012 Term B-2 Loan	May 15, 2015 Subsequent Event 2012 ABL Revolver, Amendment No. 4 2012 ABL Revolver Revolving Credit Facility	May 15, 2015 Subsequent Event 2012 ABL Revolver, Amendment No. 4 2012 ABL Revolver Revolving Credit Facility
Subsequent Event [Line Items]
Debt instrument, face amount															$ 852,500,000.0			$ 207,500,000.0	$ 645,000,000.0
Debt instrument, basis spread on variable rate (percent)																2.75%
Debt instrument, interest rate, floor (percent)																0.75%	1.75%
Interest rate, contingent margin step-down per annum (percent)																	3.25%
Revolving credit facility, increase in borrowing capacity																					35,000,000.0
Revolving credit facility, term																				5 years
Restricted common stock units granted in period, shares								5,109				185,904	163,404	22,500
Options granted, shares	10,485	307,490		422,962	317,900	227,700	444,900		186,302
Award vesting period									3 years				3 years	3 years
Percentage of options vesting annually		33.30%	33.30%						33.30%					33.30%
Award exercisability period, from date of grant (not greater than)									10 years
Options granted, weighted-average grant-date fair value (in USD per share)			$ 15.66						$ 41.44
Prior service term											22 years
Accelerated stock-based compensation cost										$ 800,000

Schedule II Valuation and Qualifying Accounts (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Reserves for Sales Returns and Allowances
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	$ 7,395	$ 6,446	$ 4,257
Amounts charged to expense	34,598	38,314	33,165
Deductions	(35,277)	(37,365)	(30,976)
Other	0	0	0
Valuation allowances and reserves, balance at end of year	6,716	7,395	6,446
Reserves for Trade Promotions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	6,101	8,523	5,506
Amounts charged to expense	60,499	39,967	41,041
Deductions	(56,668)	(42,389)	(38,024)
Other	0	0	0
Valuation allowances and reserves, balance at end of year	9,932	6,101	8,523
Reserves for Consumer Coupon Redemptions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	1,742	4,249	3,509
Amounts charged to expense	5,089	2,755	8,282
Deductions	(5,159)	(5,262)	(7,542)
Other	0	0	0
Valuation allowances and reserves, balance at end of year	1,672	1,742	4,249
Allowance for Doubtful Accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	1,035	863	604
Amounts charged to expense	340	134	265
Deductions	(98)	(6)	(6)
Other	0	44	0
Valuation allowances and reserves, balance at end of year	$ 1,277	$ 1,035	$ 863

Divestitures	12 Months Ended
Divestitures	Mar. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures Sale of the Phazyme Brand On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GlaxoSmithKline plc ("GSK") in January 2012. We received $21.7 million from the divestiture on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.

Gain on Sale of Asset	12 Months Ended
Gain on Sale of Asset	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Gain on Sale of Asset	Gain on Sale of Asset As more fully discussed in Note 8, in December 2014, we sold rights to the use of the Comet brand in certain Eastern European countries to a third-party licensee, received $10.0 million as a partial early buyout of our existing royalty agreement and recorded a gain of $1.1 million.

Business and Basis of Presentation (Property and Equipment) (Details)	12 Months Ended
	Mar. 31, 2015
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Presentation (Details)	12 Months Ended
Business and Basis of Presentation (Details)	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%
Cash equivalents, original maturities, eligibility, period	3 months

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Cumulative translation adjustment	$ (23,412)	$ 739
Accumulated other comprehensive income (loss), net of tax	$ (23,412)	$ 739

Gain on Sale of Asset (Details) (Comet Brand, USD $) In Millions, unless otherwise specified	1 Months Ended
	Dec. 31, 2014
Comet Brand
Finite-Lived Intangible Assets [Line Items]
Proceeds from early buy-out of intangible assets	$ 10.0
Gain on sale of intangible assets	$ 1.1